33rd Malaysian Urological Conference

INNOVATIONS IN UROLOGY

INTEGRATING AI & PRECISION SURGERY



MUC 2024

NOV 21-23

SETIA SPICE CONVENTION CENTRE, PENANG

Malaysia Convention & Exhibition Bureau

Meet in Malaysia BE Greater, Together.

Malaysia Truly Asia

PETAC Penang State EXCO Office for Tourism And Creative Economy

PCEB penang convention & exhibition bureau

PENANG 2030

PG

MALAYSIAN UROLOGICAL ASSOCIATION

MINISTRY OF HEALTH MALAYSIA

WHY TAKE THE RISK?

START TODAY FOR A BETTER TOMORROW

Before prescribing, please refer to the full prescribing information, which is available via scanning this QR code.
For any issues accessing the prescribing information via QR code, please contact GSK Malaysia at medinfo.my@gsk.com.

This educational program is brought to you by GSK

For Medical/Healthcare Professionals Only
Adverse events should be reported to drugsafetyinfo.my@gsk.com

GlaxoSmithKline Pharmaceutical Sdn Bhd 195801000141 (3277-U)
HZ.01, Horizon Penthouse, 1 Powerhouse, 1, Persiaran Bandar Utama, Bandar Utama,
47800 Petaling Jaya, Selangor Darul Ehsan, Malaysia.
Tel: (603) 7495 2600 www.my.gsk.com

PM-MY-DTT-PSTR-230001 03/23

Rezūm™
Water Vapor Therapy

Boston Scientific
Advancing science for life™

Rezūm nights without bathroom breaks.

Rezūm tidur lena, tanpa perlu bangun pada waktu malam.

Rezūm™ Water Vapor Therapy is a natural alternative to surgery. It treats the cause of your Benign Prostate Hyperplasia (BPH) and it is minimally invasive.

Rezūm™ Terapi Wap Air ialah alternatif semula jadi kepada pembedahan Ia merawat punca pembengkakan kelenjar prostat (BPH) dan ia adalah rawatan invasif minimal.

Seeking lasting relief from BPH symptoms?
Sedang cari kelegaan yang kekal daripada gejala BPH?

- Waking up at all hours to urinate?
  Kerap kencing pada waktu malam/tidur
- Having the urgent need to go?
  Tidak bertahan/Selalu hendak manaik tandas
- Weak stream?
  Aliran kencing perlahan/menitis
- Effects of BPH meds?
  Bimbang tentang kesan sambingan ubat

Contents

Conference Secretariat

33rd Malaysian Urological Conference
Malaysian Urological Association
Unit 6-5, Bangunan Perdagangan d6, 801 Jalan Sentul, 51000 Kuala Lumpur, Malaysia
Email: malaysianurologicalassociation@gmail.com
Website: www.muc2043.com

Message from THE Organising Chairman

Dear distinguished guests, esteemed colleagues, fellow urology professionals and friends.

A warm welcome to the prestigious Malaysian Urology Conference 2024 in the enchanting city of Penang. It's been exactly a decade since MUC was last organized here. As one of the Organizing Chairmen, it gives me great pleasure in setting up this remarkable event, which is poised to bring together the best minds in the field to explore the transformative power of artificial intelligence in urology.

The theme of this year's conference, "AI and Precision Surgery in Urology," reflects our commitment to embracing cutting-edge technologies and innovative approaches that have the potential to revolutionize patient care and outcomes. By focusing on these advancements, we aim to not only meet but exceed international standards in urological practice, and ultimately, contribute to the enhancement of healthcare services in Malaysia.

Throughout the next few days, the scientific committee have meticulously curated a program that showcases the latest research, advancements, and best practices in the intersection of AI, precision surgery, and urology. Our lineup of distinguished speakers, thought-provoking sessions, hands-on workshops, and networking opportunities are designed to be both enlightening and enriching, providing a platform for collaboration, knowledge sharing, and skill development.

I extend my deepest appreciation to all the speakers, sponsors, exhibitors, and attendees who have joined us in this endeavor to push the boundaries of urological care. Your expertise, dedication, and support are invaluable in shaping this event into a world-class experience that has the potential to drive significant improvements in healthcare services across Malaysia.

As we embark on this journey together, I urge each of you to actively engage, exchange ideas, and challenge conventional practices. Let us leverage the power of AI and precision surgery to not only optimize clinical outcomes but also to transform the way we deliver care, enhance patient experiences, and advance the field of urology in Malaysia and beyond.

May the Malaysian Urological Conference 2024 be a catalyst for new insights, collaborations, and innovations that will elevate our standards, inspire change, and pave the way for a brighter future in urological care.

A heartfelt gratitude goes out to our amazing team for their hard work and dedication. Your contributions were crucial to our success. I appreciate each one of you and look forward to our future collaborations.

Thank you.

Mr. L Sivaneswaran Lechmiannandan

Organising Chairman
33rd Malaysian Urological COnference

Message from THE Organising Chairman

Welcome to the 33rd Malaysian Urological Conference (MUC) 2024 in Pearl of the Orient, Penang!

It is my distinct honour as the organizing chairman to extend a gracious invitation to esteemed urologists, dedicated researchers, and medical professionals from around the globe to join us for our exciting annual event. This year marks a special significance as we bring the conference to the picturesque shores of Penang, a city close to my heart and rich in both culture and beauty.

MUC 2024 promises to be an unparalleled gathering, taking place as a physical conference from November 21st to 23rd at SPICE Setia Penang, Malaysia. Guided by the theme "Innovations in Urology: Integrating AI and Precision Surgery," we are poised to explore the cutting-edge advancements that are re-shaping the landscape of urological care. Get ready to dive into an epic three-day extravaganza, as our scientific programmes promise to be enlightening and dynamic, featuring insightful discussions, ground-breaking research presentations, and informative plenaries.

We are thrilled to showcase live stone surgeries, HIFU prostate and Biobot procedures, providing attendees with invaluable experience and insights into these innovative treatment modalities. Another notable highlight of our itinerary is the BPH Minimally Invasive Therapies (MIST) Workshop, which will offer young urologists a unique opportunity to hone their surgical skills through this exclusive hands-on workshop. Our distinguished line-up of speakers boasts a diverse array of local luminaries and globally renowned experts, each of whom aims to share their expertise and perspectives, enriching our collective understanding of urological practice and artificial intelligence research. MUC 2024 will feature a comprehensive exhibition where pharmaceutical and industry-leading companies can unveil their newest products.

Join us as we embark on a journey of discovery, collaboration, and innovation in this vibrant city. Together, let's immerse ourselves in the cultural and gastronomic delights of Penang, a city brimming with charm and historical significance!

We look forward to welcoming you to Penang for an unforgettable conference experience!

Warm regards,

Dr. William Ong Lay Keat

Organising Chairman
33rd Malaysian Urological Conference 2024

INNOVATIONS IN UROLOGY
INTEGRATING AI & PRECISION SURGERY

Message from THE Chairman of the Scientific Programme

Dear Friends and Colleagues,

It is with great pleasure and honor that I invite you to the 33rd Malaysian Urological Conference Scientific Meeting, hosted by the Malaysian Urological Association and the Organizing Committee. This event will take place from November 21st to 23rd, 2024, in the city of Penang, Malaysia.

The theme for this year's conference is "Innovations in Urology: Integrating AI and Precision Surgery." We stand at the precipice of transformation in medical practice, with Artificial Intelligence (AI) technologies evolving faster than anticipated. In the field of urology, renowned for our early embrace of new technologies, we are poised to take another leap forward.

We endeavor to spotlight the latest frontiers in research and celebrate evidence-based practices brought about by new technology and techniques that challenge conventional standards. While the congress theme encourages discussions on innovative treatments, we also focus on the limits of standard therapies and the impact of new research outcomes on daily urology practice.

This 3-day conference will feature live surgeries, thematic symposiums, and plenary sessions covering a wide range of contemporary and progressive topics in modern Urology. We look forward to your strong support and close collaboration to further the practice of Urology!

Yours sincerely,

Dr. Devindran Manoharan

Scientific Chairman
33rd Malaysian Urological Conference 2024

INNOVATIONS IN UROLOGY
INTEGRATING AI & PRECISION SURGERY

Message from

THE President OF THE Malaysian Urological Association

Assalamulaikum, Salam Sejahtera, Salam Malaysia Madani to everyone.

Welcome to the 33rd Malaysian Urological Conference!

On behalf of the Malaysian Urological Association (MUA), it is both an honor and a pleasure to welcome our esteemed members, invited guests, and delegates to SPICE Penang, Malaysia, for the 33rd Malaysian Urological Conference (MUC) 2024. This year's theme, "Innovations in Urology: Integrating AI & Precision Surgery," reflects the rapid advancements in technology that are transforming the field of urology.

I extend my gratitude to our Organizing Chairmen, Dr. L. Sivaneswaran and Dr. William Ong, along with our Scientific Chair, Dr. Devindran, for curating an exceptional program centered on this theme. I would like to thank our conference advisor, Dr. Git Kah Ann, for his invaluable guidance and support. The dedication, along with the efforts of the entire organizing team, has made this event possible.

We are truly privileged to host distinguished speakers from globally renowned urological associations, including BJUI, EAU, UAA, USANZ, SIU, FAUA, and NAUS. Their presence and experience will strengthen international collaborations and inspire new connections. We are pleased to have representatives from various international organizations join us at MUC 2024. Your participation enriches our gathering, and we are grateful for your commitment. Special thanks to the collaborative efforts of the hospital administration, theater coordination team, and anesthesia team, we are excited to offer pre-congress live surgeries at Hospital Pulau Pinang, which will be telecast live to conference venue.

A special note of thanks goes to our local and international speakers, whose insights and contributions will enhance the value and prestige of this conference. Our program has consistently attracted a significant number of nursing professionals, who play an important role in delivering high-quality urological care. Hence, I extend my appreciation to AUSTEG and AUNA for their essential contributions to the nursing symposium.

Beyond the scientific program, I hope all our invited speakers and delegates will also take the opportunity to enjoy the unique cultural heritage that Penang has to offer.

Finally, my sincere thanks go to our pharmaceutical and medical device industry partners for their generous support, which has been instrumental in making this conference a success.

Thank you and I wish you all a fruitful and enjoyable conference.

Dr. Noor Ashani Bin Md Yusoff

President,
Malaysian Urological Association (2022-24)

INNOVATIONS IN UROLOGY
INTEGRATING AI & PRECISION SURGERY

HELP YOUR PATIENTS WITH OAB

BENEFIT FROM TREATMENT WITH BETA-3 AGONISTS

astellas | Betmiga™ mirabegron Elevate OAB control

Beta-3 agonists such as BETMIGA™ can help avoid the side-effects of antimuscarinics while providing optimal symptom relief

OAB, overactive bladder; QoL, quality of life.

References : 1. Nitti VW, et al. J Urol. 2013;189:1388-1395. 2. Kelleher C, et al. European urology. 2018;74(3):324-333. 3. Chapple C, et al. European urology. 2015;67(1):11-4. 4. Drake MJ, et al. European urology. 2016;70(1):136-45. 5. Lozano-Ortega G, et al. Drugs Aging. 2020;37:801-816. 6. Nazir J, et al. Pharmacoecon Open. 2017;1:25-36. 7. Kato D, et al. Low Urin Tract Symptoms. 2019;11:O152-O161. 8. Soda T, et al. Neurourol Urodyn. 2020;39:2527-2534. 9. Andersson KE, et al. Ther Adv Urol. 2018;10:243-256. 10. Chapple CR, et al. Int Urogynecol J. 2013;24:1447-1458. 11. Freeman R, et al. Curr Med Res Opin. 2018;34:785-793.

BETMIGA ABBREVIATED PRESCRIBING INFORMATION

Presentation: Prolonged-release tablets containing 25 mg or 50 mg mirabegron Indication: Symptomatic treatment of urgency, increased mictunition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. **Dosage**: Adults 18 years and above (including elderly patients): The recommended starting dose is 25 mg once daily with or without food. Betmiga 25mg is effective within 8 weeks. Based on individual patient efficacy and tolerability the dose may be increased to 50 mg once daily. Renal and hepatic impaiment patients: No dose adjustment is necessary in patients with mild to moderate renai impairment. In patients with severe renal impairment, the recommended dose is 25 mg dose once daily. No dose adjustment is necessary in patients with mild hepatic impairment (Child-Pugh Class A). In patients with moderate hepatic impairment (Child-Pugh Class B) the recommended dose is 25 mg once daily.Renal impairment patient with strong CYP3A inhibitors: Mild to moderate renal impairment 25 mg once daily. Severe renal impairment not recommended. Hepatic impairment patient with strong CYP3A inhibitors: Mild hepatic impairment (Child-Pugh Class A) 25 mg once daily Moderate hepatic impaiment (Child-Pugh Class B) not recommended. **Method of Administration**: Betriga is to be taken once daily, with liquids, swallowed whole and is not to be chewed, divided, or crushed. Contraindication: Hypersensitivity to the active substance or to any of the excipients listed in section list of excipients. Severe uncontrolled hypertension defined as systolic blood pressure 2180 mm Hg and/or diastolic blood pressure 2110 mm Hg. **Special Precautions**: Renal impairment Betmiga has not been studied in patients with end stage renal disease (GFR <15 mL/min/1.73 m or patients requiring haemodialysis) and therefore, it is not recommended for use in this patient population. Data are imited in patients with severe renal impairment (GFR 15 to 29 mL/min/1.73mbased on a pharmacokinetic study (see full prescribing information) a dose reduction to 25 mg is recommended in this population. Betriga is not recommended for use in patients with severe renal impairment (GFR 15 to 29 mL/min/1.73m.) concomitantly receiving strong CYP3A inhibitors (see full prescribing information). Hepatic impairment: Betmiga has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and therefore, it is not recommended for use in this patient population Betriga is not recommended for use in patients with moderate hepatic impairment (Child-Pugh B) concomitanty receiving strong CYP3A inhibitors (see full prescribing information. Increases in Blood Pressure: Mirabegron can increase blood pressure. Blood pressure should be measured at baseine and periodically during treatment with Betmiga, especially hypertensive patients. Data are limited in patients with stage 2 hypertension systolic blood pressure 2 160 mm Hg or diastolic blood pressure 2100 mm Hg). In two, randomized, placebo-controlled, healthy volunteer studies, Betmiga was associated with dose-related increases in supine blood pressure. In these studies at the maximum recommended dose of 50 mg, she mean maximum increase in systolic diastolic blood pressure was approximately 3.5/1.5 mmHg greater than placebo. In contrast, in OAB patients in clinical trials, the mean increase in systolic and diastolic blood pressure at the maximum recommended dose of 50 mg was approximately 0.5-1 mmHg greater than placebo. Worsening of preexisting hypertension was reported in frequently in Betriga patients. Patients with congenital or acquired QT prolongation: Betmiga, at therapeutic doses, has not demonstrated clinically relevant QT prolongation in clinical Studies (see ful prescribing information. However, since patients with a known history of QT prolongation or patients who are taking medicinal products known to prolong the QT interval were not included in these studies, the effects of mirabegron in these patients is unknown. Caution should be exercised when administering mirabegon in these patients. Patients with bladder outlet obstruction and patients taking animuscarinics medications for OAB: Urinary retention in patients with bladder outlet obstruction (800) and in patients taking antimuscarinic medications for the treatment of OAB has been reported in postmarketing experience in patients taking mirabegron. A controlled dinical safety study in patients with BOO did not demonstrate increased urinary retention in patients treated with Betmiga, however, Betriga should be administered with caution to patients with dinically significant 800. Betmiga should also be administered with caution to patients taking antimuscarinic medications for the treatment of OAB. Interactions: Inhibitory effect on the metabolism of CYP2D6 substrates. Betmiga is a moderate and time-dependent inhibitor of CYP2D6 and weak inhibitor of CYP3A. Increased AUC in the presence of the strong inhibitor of CYP3AP-gp ketoconazole. Caution if co-administered with medicines with a namow therapeutic index and significantly metabolised by CYP2D6. When initiating in combination with digoxin the lowest dose for digoxin should be prescribed and serum digoxin should be monitored. **Undesirable Effects**: Summary of the safety profile: The safety of Betmiga was evaluated in 8433 patients with OAB, of which 5648 received at least one dose of mirabegron in the phase 2/3 clinical program, and 622 patients received Betmiga for at least 1 year (365 days). In the three 12-week phase 3 double blind, placebo controlled studies, 88% of the patients completed treatment with Betmiga, and 4% of the patients discontinued due to adverse events. Most adverse reactions were mid to moderate in severity. The most common adverse reactions reported for patients treated with Betmiga 50 mg during the three 12-week phase 3 double blind, placebo controlled studies are tachycardia and urinary tract infections. The frequency of tachycardia was 1.2% in patients receiving Betmiga 50 mg. Tachycardia led to discontinuation in 0.1% patients receiving Betmiga 50 mg. The frequency of urinary tract infections was 2.9% in patients receiving Betmiga 50 mg. Urinary tract infections led to discontinuation in none of the patients receiving Betmiga 50 mg. Serious adverse reactions included atrial Filation (0.2%. Adverse reactions observed during the 1-year long term) active controlled (muscarinic antagonist) study were similar in type and severity to those observed in the three 12-week phase 3 double blind, placebo controlled studies. Tabulated list of adverse reactions. The table below reflects the adverse reactions observed with mirabegon in the three 12-week phase 3 double bind, placebo controlled studies. The frequency of adverse reactions is defined as follows: very common (21/10): common 21/100 to <1/10); uncommon (21/1,000 to <1/100); rare (21/10.000 <1/1.000): very rare (<1/10,000). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness Infections and infestations: Common Urinary tract infection: Uncommon: Vaginal infection Cystitis Psychiatric disorders: Not known: Insomnia observed during post-marketing experience. Eye disorders: Rare: Eyelid oedema. Cardiac disorders: Common: Tachycardia: Uncommon: Palpitation, Atrial fibrillation. Vascular disorders: Very rare: Hypertensive crisis (observed during post-marketing experience). Gastrointestinal disorders: Common: Nausea (observed during post-marketing experience), Constipation observed during post-marketing experience), Diamhoea observed during post-marketing experience); Uncommon: Dyspepsia, Gastritis, Rare: Lip oedema. Skin and subcutaneous tissue disorders: Uncommon: Urticaria, Rash, Rash macular, Rash popular, Pruritus, Rare: Leukocytoclastic, vasculitis, Purpura Angioedema (observed during post-marketing experience. Musculoskeletal and connective tissue disorders: Uncommon: Joint swelling. Reproductive system and breast disorders: Uncommon Vulvovaginal, pruritus. Investigations: Uncommon Blood pressure increased, GGT increased. AST increased, ALT increased. Renal and urinary disorders: Rare: Urinary retention (observed during post-marketing experience). Nervous system disorders: Common: Headache (observed during post-marketing experience), Dizziness (observed during post-marketing experience). Packs: 30 prolonged-release tablets of 25 mg, 50 mg. API date: 29 Jan 2018.

astellas
Astellas Pharma Malaysia Sdn Bhd
Suite 18.05, Level 18, Centrepoint North Tower, Mid Valley City, Lingkaran Syed Putra, 59200 Kuala Lumpur.
Tel: +603-2202 6999 Fax: +603-2202 6988/977 www.astellas.com

For Healthcare Professional Only
MAT-MY-BET-2024-00024

ORGANISING COMMITTEE

Advisor	Git Kah Ann & Noor Ashani Md Yusoff
Chairman	L. Sivaneswaran Lechmiannandan & William Ong Lay Keat
Scientific Program Chair	Devindran Manoharan
Abstract and Publication Chair	Omar Ahmed Fahmy Ahmed
Nursing Program Chair	Ch'ng Ling Sing
Social Chair	Lee Chin Yiun
Pre-Congress Workshop	Kumarappan Alagappan
Endourology Night	Git Kah Ann

MALAYSIAN UROLOGICAL ASSOCIATION EXECUTIVE COMMITTEE (2022 – 2024)

President	Noor Ashani Md Yusoff
Vice President	Shanggar Kuppusamy
Hon Secretary	Vijayan Manogran
Hon Treasurer	Toh Charng Chee
Committee members	Khairul Asri Mohd Ghani Goh Yue Keng L. Sivaneswaran



INNOVATIONS IN UROLOGY
INTEGRATING AI & PRECISION SURGERY

INVITED FACULTY

MALAYSIA

Alex Khoo Cheen Hoe
Azilawati Hanim binti Ghozali
Ch'ng Ling Sing
Chew Bee See
Clarence Lei Chang Moh
Datesh Daneswar
Desmond Ling Chung Wei
George Lee
Git Kah Ann
Kumarrapan Alagappan
L Sivaneswaran Lechmiannandan
Lim Li Yi
Ngoo Kay Seong
Noor Ashani Md Yusoff
Nur Azreen Abdul Aziz
Poongkodi Nagappan
Roger Anthony Idi
Shankaran Thevarajah
Sritharan Subramaniam
Sun Kian Joo
Suriaraj Karpayya
Syahril Anuar Salauddin
Syarah Zakaria
Tan Ai Lian
Tan Jin Rong
Taniza Ahmad
William Ong Lay Keat
Wong Peng Shyan

AUSTRALIA

Marinelle Doctor
Rick Catterwell

CHINA

Zeng Guohua
Khai Zhang

HONG KONG

Lo Ka Lun

INDONESIA

I Wayan Yudiana
Paksi Satyagraha

INDIA

Rajesh Taneja
Uttam Mete

JAPAN

Akio Horiguchi

NEPAL

Bhojraj Luitel
Manish Man Pradhan
Sanjay Khadgi

SINGAPORE

Daniel Yong Zhan Peng
Tiong Ho Yee
Nuraishah binte Zulkifli

TAIWAN

Lin Po-Hung
Allen W Chiu

THAILAND

Tanan Bejrananda

UNITED ARAB EMIRATES

Ranjith Ramasamy

UNITED KINGDOM

Axel Bex
Christopher Eden
Max Cervellione
Mehwash Nadeem
Param Mariappan
Simon Choong

UNITED STATES OF AMERICA

Murugesan Manoharan

GSK

IF YOU CAN PREVENT SHINGLES SUFFERING, WHY WOULDN'T YOU?[1]

SHINGRIX
(ZOSTER VACCINE RECOMBINANT, ADJUVANTED)

NOW APPROVED IN MALAYSIA

YOU CAN NOW PROTECT YOUR PATIENTS WITH SHINGRIX.

INDICATIONS
Shingrix is indicated for the prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in

- **≥50** Adults 50 years of age or older[1]
- **≥18** Adults 18 years of age or older at increased risk of HZ[1]

MSIDC and CDC recommends vaccinating your patients **≥ 50 years with 2 doses of SHINGRIX**.[2,4]

97% **Protection that lasts. SHINGRIX offers 97% efficacy** to adults ≥ 50 years, and **91%** to adults ≥ 70 years.[1*]

Established safety profile. Most vaccination reactions were **mild to moderate, with a median duration of 2 - 3 days.**[3†]

SHINGRIX is given as a 2-dose series. For ≥ 50 years old, 2nd dose should be administered 2 months after 1st dose. If flexibility is necessary, it can be administered between 2 - 6 months after.[1]

VACCINATE NOW FOR PROTECTION THAT LASTS UP TO 10 YEARS[1]

Median follow-up period of 3.1-4 years in ZOE-50/70.[1]
* 97.2% (95% CI: 93.7; 99.0) VE against confirmed shingles in subjects ≥ 50 years in ZOE-50, 91.3 (95% CI: 86.8; 94.5) VE against confirmed shingles in subjects ≥ 70 years in pooled data from ZOE-50 and ZOE-70.[1]
† Median duration of 3 days or less for local symptoms and 2 days or less for general symptoms.[3]

References: 1. Shingrix Prescribing Information. **2.** Centers for Disease Control and Prevention. Shingles vaccination. Reviewed May 8, 2023. Accessed May 8, 2024. https://www.cdc.gov/vaccines/vpd/shingles/public/Shingrix/index.html. **3.** López-Fauqued M, et al. Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials. *Vaccine.* 2019;37:2482-93. **4.** Guideline for Adult Immunization - 3rd Edition, Malaysia Society of Infectious Diseases and Chemotherapy (Published in October 2020, Revised in November 2023), Page 187.

For Malaysia Healthcare Professionals Only
Adverse events should be reported to drugsafetyinfo.my@gsk.com

GlaxoSmithKline Pharmaceutical Sdn Bhd 195801000141 (3277-U)
HZ.01, Horizon Penthouse, 1 Powerhouse, 1, Persiaran Bandar Utama, Bandar Utama, 47800 Petaling Jaya, Selangor Darul Ehsan, Malaysia.
Tel: (603) 2037 9808 www.my.gsk.com

Before prescribing, please refer to the full prescribing information, which is available via scanning this QR code.
For any issues accessing the prescribing information via QR code, please contact GSK Malaysia at medinfo.my@gsk.com.

PM-MY-SGX-LBND-240007 09/24

PRE-CONGRESS LIVE SURGERY

21st November 2024 [Thursday]
Ballroom 4, Lower Ground Level, Setia SPICE Convention Centre

ACC OT 1 (Prostate)

Time	Surgery	Surgeon
0900 - 1000	**Robotic Transperineal Prostate Biopsy- BIOBOT**	Sritharan Subramaniam
1000 - 1130	**Nanoknife for Focal Therapy of Prostate**	Murugesan Manoharan
1130 - 1300	**Rezum for BPH**	Lo Ka Lun
1300 - 1400	**Lunch Symposium** by by Transmedic Healthcare Sdn Bhd **The Science of Personalized Spacing** *Speaker :* Michael Chao and Peter Ng Eng Pin *Moderator :* Tan Guan Hee	
1400 - 1600	**HIFU for Focal Therapy of Prostate**	Sivaneswaran Lechimianandan

ACC OT 2 (Stone)

Time	Surgery	Surgeon
0900 - 1100	**Enhanced Super Mini PCNL**	Zeng Guohua
1100 - 1300	**RIRS with FANS**	Simon Choong
1300 - 1400	**Lunch Symposium** by by Transmedic Healthcare Sdn Bhd **The Science of Personalized Spacing** *Speaker :* Michael Chao and Peter Ng Eng Pin *Moderator :* Tan Guan Hee	
1400 - 1600	**Mini PCNL**	Sanjay Khadgi

For Healthcare Professionals Only.
MY-15908_NOV2024

Zoladex®
goserelin

"ONE CLICK" FOR RAPID RESPONSE & SUSTAINED SERUM TESTOSTERONE SUPPRESSION IN PROSTATE CANCER MANAGEMENT[7]

10+ YEARS data[1,2]

On overall survival in localised PCa patients and reduction in risk of progression in locally advanced PCa patients[1,2].

Generally Well Tolerated[3,4]

Very common (≥1/10) adverse events in men include erectile dysfunction, hot flushes, hyperhidrosis and libido decreased[3,4].

~100% Bioavailability[3,4]

Pre-filled dose that ensures patient will receive the same, full dose every time[3,4].

1 Step Administration[5]

Fast and quick administration with less than 2 minutes injection time[5].

Needle size doesn't matter[6]

The majority of patients report minimal pain (VAS<10 mm) from ZOLADEX injections[6].

Safe System™[5]

Minimal exposure risk as needle is automatically covered upon withdrawal[5].

Scan here for: Full Prescribing Information

Administration Video

AstraZeneca
AstraZeneca Sdn Bhd (69730-X)
The Bousteador Tower, Level 12,
No. 10, Jalan PJU 7/6, Mutiara Damansara,
47800, Petaling Jaya, Selangor, Malaysia.
T: +60 3 7624 3888 F: +60 3 7624 399

References: 1. Carrie C, Magne N, Burban-Provost P, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU16): a 112-month follow-up of a phase 3, randomised trial. *Lancet Oncol*. 2019;6. 2. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. *Lancet Oncol*. 2010;11(11):1066-1073. 3. ZOLADEX 3.6mg Malaysia Prescribing Information. Doc ID-002717410 V7; June 2022. 4. ZOLADEX 10.8mg Malaysia Prescribing Information. Doc ID-002717344 V8; June 2022. 5. Kaisary AV, Tyrrel CJ, Peeling WB, Griffiths K.Comparison of LHRH analogue (ZOLADEX) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol. 1991;67(5):502-508.6. Vogelzang NJ, Chodak GW, Soloway MS, et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology. 1995;46:220-226. 7. Fernandez del Moral P et al. Urology. 1996; 48(6):894-900.

DAY 1 22nd November 2024 [Friday]

Venue : **Ballroom 3, Lower Ground Floor, Setia SPICE Convention Centre**

Time	Event / Topic	Speaker
0730 - 0800	Registration	
Plenary 1: Bladder Cancer *Chairperson :* Fam Xeng Inn & Toh Charng Chee		
0800 - 0815	**UAA Lecture :** Revolutionizing Cystoscopy: Harnessing the Power of Artificial Intelligence (AI)	Allen W Chiu
0815 - 0830	**TUA Lecture (Taiwan) :** En-bloc resection of bladder tumour - Is it a relevant approach?	Po-Hung Lin
0830 - 0845	Immunotherapy in Locally Advanced and Metastatic UTUC	Tan Ai Lian
0845 - 0900	Contemporary Management of Non-Metastatic Bladder Cancer	Param Mariappan
0900 - 0910	Q&A	
0910 - 0940	**Morning Tea Symposium** by Zuellig Pharma (M) Sdn Bhd **LIFTing Limitations: Sexual Health in the Face of BPH** *Speaker:* Christopher Ho Chee Kong	
0940 - 1010	**Opening Ceremony** followed by Exhibition Visit	Org Comm MUC/MUA
1010 - 1030	Morning Tea Break	
Plenary 2: Urolithiasis (IAU session) *Chairperson :* Git Kah Ann & Teoh Boon Wei		
1030 - 1045	**SIU Lecture :** Embracing Artifical Intelligence in Urolithiasis Management	Paksi Satyagraha
1045 - 1100	fURS versus PCNL for Larger Stones in this Modern Era?	Sanjay Khadgi
1100 - 1115	Is Flexible-Navigable Suction Ureteral Access Sheath (FANS) a Game Changer in RIRS?	Simon Choong
1115 - 1130	Downsizing PCNL: Unveiling the Intriguing World of Miniaturization	Zeng Guohua
1130 - 1140	Q&A	

DAY 1 22nd November 2024 [Friday]

Venue : **Ballroom 3, Lower Ground Floor, Setia SPICE Convention Centre**

Time	Event / Topic	Speaker
Plenary 3: Paediatric Urology & Signing fo Memorandum of Understanding *Chairperson :* Poongkodi Nagappan & Roger Anthony Idi		
1140 - 1155	Minimally Invasive Approaches in Varicocele Surgery: 15-year Manchester experience	Max Cervellione
1155 - 1210	Adolescent and Adult Urological Care for Patients with Exstrophy/epispadias	Max Cervellione
1210 - 1225	Botulinum Toxin Injection vs Augmentation Cystoplasty for Patients with Neuropathic Bladder	Lim Li Yi
1225 - 1235	Q&A	
1235 - 1255	**Signing of Memorandum of Understanding for Training and Research Collaboration between Department of Paediatric Urology, Royal Manchester Children's Hospital and Malaysian Urological Association**	
1255 - 1355	**Lunch Symposium** by Ipsen Pharma Singapore Pte Ltd **Living with ADT: The Backbone of Prostate Cancer Management** *Speaker :* Toh Charng Chee *Chairperson :* Noor Ashani Md Yusoff	
Plenary 4: BPH and Andrology *Chairperson :* Zulkifli Md Zainuddin & Devindran Manoharan		
1400 - 1415	**USANZ Lecture :** Large Prostate Management - HoLEP vs Staging TURP	Rick Catterwell
1415 - 1430	Management of Azoospermia	Ranjith Ramasamy
1430 - 1445	Minimal Invasive Surgery Therapy for BPE - less is more with rezum, iTIND, urolift	Lo Ka Lun
1445 - 1500	Revolutionizing BPH Progression Prediction with Machine Learning Models	Bhojraj Luitel
1500 - 1515	Restorative Treatment for Erectile Dysfunction	George Lee

DAY 1 22nd November 2024 [Friday]

Venue : **Ballroom 3, Lower Ground Floor, Setia SPICE Convention Centre**

Time	Event / Topic	Speaker
1515 - 1525	**Soft Launch Malaysian CPG on Erectile Dysfunction**	
1525 - 1555	**Afternoon Tea Symposium** by J&J Sdn Bhd **The Evolving Landscape of Systemic Therapies in the Management of mCSPC – A Personalized Approach** *Speaker:* Ng Chi Fai *Chairperson:* Sritharan Subramaniam	
Plenary 5: Prostate Cancer *Chairperson :* Khairul Astri Mohd Ghani & Tan Guan Hee		
1555 - 1610	Predicting Patient Outcomes after Robotic Surgery and Automating Skills Assessment	Christopher Eden
1610 - 1625	AI Pathology in Prostate Cancer	Chew Bee See
1625 - 1640	**SUA Lecture :** Radical Therapy in Oligometastatic Prostate Cancer	Danial Yong
1640 - 1655	Catapult PSMA PET Imaging into Forefront Diagnosis of Prostate Cancer	Alex Khoo Cheen Hoe
1655 - 1705	Focal Therapy in Prostate Cancer	Murugesan Manoharan
	Q&A	
1705 - 1715	Afternoon Tea Break	
1730 - 1930	**MUA AGM**	

DAY 2 — 23rd November 2024 [Saturday]

Venue : **Ballroom 3, Lower Ground Floor, Setia SPICE Convention Centre**

Time	Event / Topic	Speaker
0800 - 0830	**Breakfast Symposium** by Viatris Sdn Bhd **Collaborative Care in Sexual Health: The Legacy and Future Perspectives** *Speaker :* Lo Hwa Loon	
	Plenary 6: Reconstruction *Chairperson :* Hamid Haji Ghazali & Saiful Azli Mohd Zainuddin	
0830 - 0845	Management of Short Bulbar Urethral Stricture: When to transect and when not to transect	Akio Horiguchi
0845 - 0900	Reconstruction for Posterior Urethral Stricture due to PFU	Paksi Satyagraha
0900 - 0915	Surgical Modalities for Correction of Penile Paraffinoma	Syahril Anuar Salauddin
0915 - 0930	Penile prosthesis : Tips and Tricks	Ranjith Ramasamy
0930 - 0940	Q&A	
0940 - 1010	**Morning Tea Symposium** by Astellas Pharma (M) Sdn Bhd **Navigating the Landscape of Locally Advanced and Metastatic Urothelial Carcinoma: Diagnosis and Treatment Paradigms** *Speaker :* Teh Guan Chou *Chairperson :* Loh Chit Sin	
1010 - 1025	Morning Tea Break	
	Plenary 7: Renal Cancer *Chairperson :* J.R Sathiyananthan & Yeoh Wei Sien	
1025 - 1040	**EAU Lecture :** Artificial Intelligence to Predict Recurrence after Surgical Resection of Non-metastatic Renal Cell Carcinoma: Is It Any Better than Conventional Systems?	Axel Bex
1040 - 1055	EAU update on RCC 2024	Axel Bex

DAY 2 — 23rd November 2024 [Saturday]

Venue : **Ballroom 3, Lower Ground Floor, Setia SPICE Convention Centre**

Time	Event / Topic	Speaker
1055 - 1110	Robotic Partial Nephrectomy: Pushing The Boundaries	Rick Catterwell
1110 - 1125	**TUA Lecture (Thailand) :** Focal Therapy for Small Renal Mass	Tanan Bejrananda
1125- 1135	Q&A	
Plenary 8: Functional Urology *Chairperson :* Siti Nur Masyithah Ma'arof		
1135 - 1150	Integrating AI in Intestitial Cystitis/ Bladder Pain Syndrome	Rajesh Taneja
1150 - 1220	**IC/BPS Case Panel Expert Discussion** *Panellists :* Lo Hwa Loon, Poongkodi Nagappan, Bhojraj Luitel, Mahesh Bahadur Adhikari	Rajesh Taneja
1220 - 1235	**BJUI Lecture :** Post-Operative Urinary Incontinence	Mehwash Nadeem
1235 - 1245	Q&A	
1245 - 1345	**Lunch Symposium** by GlaxoSmithKline Pharmaceutical Sdn Bhd **Medical Management of BPH : Progression** *Speaker :* Devindran Manoharan *Chairperson :* Ngoo Kay Seomg	
Plenary 9: Penis & Testicular Cancer *Chairperson :* Lee Say Bob & Chang Bing Chi		
1345 - 1400	Penile Preserving Surgery - Pushing Boundaries	Shankaran Thevarajah
1400 - 1415	**USI Lecture :** Robotic RPLND	Uttam Mete
1415 - 1430	**InaUA Lecture :** Updates on Nodal Disease Management in Penile Cancer	I Wayan Yudiana
1430 - 1440	Q&A	

DAY 2 23rd November 2024 [Saturday]

Venue : **Ballroom 3, Lower Ground Floor, Setia SPICE Convention Centre**

Time	Event / Topic	Speaker
	Plenary 10: Young Urologist Fellowship / Education and Training *Chairperson :* Rohan Malek & Noor Azam Nasuha	
1440 - 1455	Future of Urology Training in Malaysia	Noor Ashani Md Yusoff
1455 - 1510	Beyond Borders: Enhancing Malaysian Urology through Research and Training	Param Mariappan
1510 - 1525	The Role of Public-private Partnership in Urology Training	Clarence Lei Chang Moh
1525 - 1540	Utilizing Social Media in Producing Research in Current Era	William Ong Lay Keat
1540 - 1550	Q&A	
1550 - 1620	**Afternoon Tea Symposium** by AstraZeneca Sdn Bhd **The Great ADT Debate : Picking Your Prostate Treatment Champion** *Speaker :* Goh Yue Keng and Toh Charng Chee *Chairperson :* Fam Xeng Inn	
	Plenary 11: Infections *Chairperson :* Goh Yue Keng & Karthika Ramasmy	
1620 - 1635	Low Intensity Shockwave in Treatment for CPPS	Datesh Daneshwar
1635 - 1650	**NAUS Lecture :** Efficacy of Antimicrobial Intravesical Treatment for Uncomplicated Recurrent Urinary Tract Infections: A Systematic Review	Manish Man Pradhan
1650 - 1705	Prophylatic Antibiotic Choices in Urological Surgeries	Kumarappan Alagappan
1705 - 1720	Case Scenario in Urological Infection: From the Urologist and Infectious Disease Physician's Perspective	Wong Peng Shyan & Git Kah Ann
1720 - 1730	Tea Break	
1930 - 2230	**Conference Dinner**	

Diphereline® Can Support Your Patient Journey

Diphereline® - Potent GnRH agonist proven to suppress testosterone below castrate levels* to extend the lives of men living with advanced PCa[1-5]

Effective treatment of advanced PCa

Achieve early and sustained castration† with all **Diphereline®** formulations[5-8]

Backbone therapy

Add additional therapies to **Diphereline®** treatment when disease progresses despite castration‡[1-4]

*Serum testosterone ≤50 ng/dL or <20 ng/dL; †Serum testosterone levels ≤50 ng/dL were achieved within 2–4 weeks of initiating therapy and maintained for up to 48 weeks in studies of 1-, 3- and formulations of Diphereline®[1–3,6–9]; ‡Testosterone levels must be confirmed to be <50 ng/dL before diagnosing CRPC[11]
Abbreviations GnRH: Gonadotropin-releasing hormone; PCa: Prostate cancer.

References :
1. NCCN Guidelines Prostate Cancer Version 4. 2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf **2**. Parker C, Castro E, Fizazi K, et al. Ann Oncol. 2020;31(9):1119–1134 **3**. Merseburger A, Hammerer P, Rozet F, et al. World J Urol. 2015:33:1079–1085. **4**. Gil T, Aoun F, Cabri P, et al. Ther Adv Urol. 2015;7(3):116–124. **5**. Malaysia Diphereline Approved PI **6**. Teillac P.Heyns C,Kaisary A et Al.Harms Res .2004;62(5):252-258 **7**. Lundstram EA,Rencken RK, van Wyk JH, et al.Clin Drug Investing .2009;29(12):757-765 **8**. Breul J. Lundstrom E,Purcera D et al Adv Ther 2017;34 (2):513-523

Abridged Prescribing Information
Trade Name: Diphereline® (Triptorelin)P.R. Powder and Solvent for Suspension for Injection 3.75mg/vial **Administration: Prostate Cancer:** one IM injection every 4 weeks **Genital and Extragenital Endometriosis (Stage I to Stage IV):** one IM injection every 4 weeks (initiated in the first 5 days of the menstrual cycle and should not be administered for more than 6 months) **Uterine fibromyomas prior to surgery:** one IM injection every 4 weeks (initiated in the first 5 days of the menstrual cycle, studies were conducted for durations between 3 to 4 months). **Precocious puberty (before 8 years in girls and 10 years in boys):** children under 20kg: (1/2) a dose by IM route, every 4 weeks children between 20 and 30kg: 2/3 of the dose by IM route, every 4 weeks; children over 30kg: one IM injection every 4 weeks. **Breast cancer:** one intramuscular injection every 4 weeks in combination with tamoxifen or an aromatase inhibitor, treatment should be initiated after completion of chemotherapy (once pre-menopausal status has been confirmed) and at least 6-8 weeks (minimum 2 injections) before starting aromatase inhibitor treatment.

Trade Name: Diphereline® (Triptorelin)P.R. Powder and Solvent for Suspension for Injection 11.25mg/vial. **Administration: Prostate Cancer:** one intramuscular or subcutaneous injection every 3 months. **Genital and Extragenital Endometriosis (Stage I to stage IV):** one IM injection every 3 months (initiated in the first 5 days of the menstrual cycle and for at most 6 months **Precocious puberty (before 8 years in girls and 10 years in boys):** Children over 20 kg in body weight, one IM injection every 3 months [Common cautions] **Contraindications:** Hypersensitivity to GnRH, its analogues or to any of the excipients; pregnancy and breast feeding; in the pre-menopausal breast cancer setting, initiation of aromatase inhibitor treatment before adequate ovarian suppression with triptorelin has been achieved. **Special Warnings & Precautions:** Non-pregnancy should be confirmed, A non-hormonal method of contraception should be used. Treatments may cause reduction in bone mineral density; may reveal the presence of a previously unknown gonadotroph cell pituitary adenoma; increase risk of incident depression. Caution should be given to patients treated with anti-coagulants or drugs having an impact on QT interval **Undesirable Effects:** In men: the most commonly observed adverse events related to triptorelin treatment were due to its expected pharmacological effects: initial increase in testosterone levels, followed by almost complete suppression of testosterone. These effects included hot flushes (50%), erectile dysfunction (4%) and decreased libido (3%). In women: the most commonly reported adverse events (expected in 10% of women or more) were headache, libido decreased, sleep disorder, mood altered, dyspareunia, dysmenorrhoea, genital haemorrhage, ovarian hyperstimulation syndrome, ovarian hypertrophy, pelvic pain, abdominal pain, vulvovaginal dryness, hyperhidrosis, hot flushes. In children: vaginal bleeding including spotting, hypersensitivity reaction, headache, hot flushes, abdominal pain, injection site reaction, weight increase. Revision date: August 2024
Malaysia PI 3.75mg (Date of Revision: Oct 2023) Malaysia PI 11.25mg (Date of Revision: May 2024)

Full prescribing information is available upon request, please refer to full prescribing information before prescribing. For adverse events reporting, please report to zpmypv@zuelligpharma.com

IPSEN **Ipsen Pharma Singapore Pte Ltd**
Twenty Anson, 20 Anson Road, #10-03,Singapore 079912
+65 6850 0700

FOR HEALTHCARE PROFESSIONAL USE ONLY DIP-MY-000418 September 2024

NURSING SYMPOSIUM

- **22nd November 2024**
- **Ballroom 4, Lower Ground Floor, Setia SPICE Convention Centre, Penang**

Moderators:

Ch'ng Ling Sing and Ngoo Kay Seong
In Collaboration with AUSTEG and AUNA

Time	Topics	Speaker
0910 - 0940	**Morning Symposium**	
0940 – 1010	Opening Ceremony	
1010 – 1030	Morning Tea Break	
1030 - 1130	**Stones & Infection**	
	- Nursing care of ureteral stent related symptoms and the prevention of urinary stone	Khai Zhang
	- Catheter care and prevention of Urinary Tract Infection	Marinelle Doctor
	- Innovations in urological instrumentation management	Taniza Binti Ahmad
	- Q&A	
1130 - 1220	**Paediatrics Urology**	
	- Preparing for stone surgery for children	Nur Azren Binti Abdul Aziz
	- Tiny steps, big impact: Empowering nurses to Teach Clean intermittent catheterization in Children	Syarah Binti Zakaria
	- Expert insights into Transition care counselling	Ch'ng Ling Sing
	- Q&A	
1220 - 1250	**Sponsored session by Rapha** - Empowering nurses in daycare urology	Ngoo Kay Seong
1250 - 1340	**Lunch Symposium**	
1400 - 1500	**Uro-oncology**	
	- Nurse- led innovations in Advanced prostate cancer management	Ngoo Kay Seong
	- From Surgery to Recovery: Nursing strategies and stoma care after Radical Cystectomy	Suriaraj Karppaya
	- Dispelling Myths and Cultivating Hope in the cancer journey	Nursaishah Zulkifle
	- Q&A	
1500 - 1700	**Urodynamic Masterclass**	
	• Lecture series: UDS basics + troubleshooting	Lim Li Yi
	• UDS practicals	MKS representatives
	• Bladder scan – hands-on	
	Adjourn	

REdefine your prostate cancer management by placing deep PSA reduction as a treatment goal

How does a deep PSA response with Erleada® benefit mHSPC patients?

mHSPC patients on Erleada® who achieved a deep PSA response **survived longer**[1]

OS by PSA ≥ 90% response



Adapted from Chi KN, et al. J Urol. 2021.

mHSPC patients on Erleada® who achieved PSA ≤ 0.2 ng/mL experienced **increased time until deterioration of QOL parameters**[2]

FACT-P total	▲ 29.4 months HR 0.54
FACT-P physical well-being	▲ 14.7 months HR 0.63

Adapted from Small EJ, et al. J Clin Oncol. 2022.

Erleada® in Asian patients: A TITAN subgroup analysis

More patients on Erleada® achieved PSA50 and PSA90 response from 3 months[3]



Adapted from Ye DW, et al. Poster session presented at: 42nd Congress of the Society International of Urology; 2022.

Choose Erleada® for a rapid, deep and durable PSA reduction in your prostate cancer patients[3]

- Improved quality of life[2]
- Longer survival[1]

More patients on Erleada® achieved PSA90 vs. enzalutamide and abiraterone acetate[4,5]

References

1. Chi KN, Saad F, Chowdhury S, et al. Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide: Results from the TITAN and SPARTAN studies. Presentation PD34. J Urol. 2021;206(3S):e587. **2.** Small EJ, Chi KN, Chowdhury S, et al. Association between patient-reported outcomes and changes in prostate-specific antigen in patients with advanced prostate cancer treated with apalutamide in the SPARTAN and TITAN studies. J Clin Oncol. **3.** Ye DW, Uemura H, Chung BH, et al. Prostate-specific antigen kinet ics in mCSPC patients treated with apalutamide: the post-hoc analysis of TITAN study in Asian subgroup. Poster session presented at: 42nd Congress of the Society International of Urology; 2022 November 9-13, Montreal, Quebec, Canada.2022;40(6_suppl):73. **4.** Lowentritt B, Pilon D, Khilfeh I, et al. Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide. J Clin Oncol. 2022;40(6_suppl):43-43. **5.** Lowentritt B, Brown G, Pilon D, et al. Real-world comparison of deep prostate-specific antigen response in patients treated with apalutamide or abiraterone acetate for metastatic castration-sensitive

ADT: androgen deprivation therapy; **mHSPC:** metastatic hormone-sensitive prostate cancer; **NR:** not reached; **OS:** overall survival; **PSA:** prostate-specific antigen; **HR:** hazard ratio; **CI:** confidence interval; **FACT-P:** Functional Assessment of Cancer Therapy-Prostate; **QoL:** quality of life.

Erleada® (apalutamide) 60 mg tablets

For the full Erleada® prescribing information, please scan the QR code.

Johnson & Johnson Sdn. Bhd.
Level 8, The Pinnacle, Persiaran Lagoon, Bandar Sunway,
46150 Petaling Jaya, Selangor, Malaysia
Tel: 03-7661 4500

Creation date: May 2024
Creation number: CP-452219

For Healthcare Professionals only.

Johnson&Johnson

DAY 2 BREAKOUT SESSION

23rd November 2024 • **Ballroom 4, Lower Ground Floor, Setia SPICE Convention Centre, Penang**

Time	Topics	Speaker
0800 - 0830	**Breakfast Symposium** by Viatris Sdn Bhd	
0830 - 0940	Podium and Poster Presentations	
0940 - 1010	**Morning Tea Symposium** by Astellas Pharma (M) Sdn Bhd	
1010 - 1025	Tea Break	
Exstrophy-Epispadias - Study Day Chairpersons: Ch'ng Ling Sing and Kamal Raj Perumal		
Surgical Repair Techniques		
1030 - 1045	Welcome Address Embryology of Exstrophy/epispadias and Historical Overview of Repair Techniques	Poongkodi Nagappan
1045 - 1100	Kelly Procedure for Bladder Exstrophy: My Observations of the Great Ormond Street Hospital Experience	Roger Anthony Idi
1100 - 1115	Modern Staged Repair (MSRE) Technique: Case study	Tan Jin Rong
1115 - 1125	Q&A	
Renal Outcome		
1125 - 1140	Early Identification of Chronic Kidney Disease (CKD) in Children with CAKUT and Measures to Slow Down CKD Progression	Azilawati Hanim binti
1140 - 1155	Deterioration of Renal Function during Adolescence: Case Study	Sun Kian Joo
1155 - 1205	Q&A	

DAY 2 BREAKOUT SESSION

23rd November 2024 • **Ballroom 4, Lower Ground Floor, Setia SPICE Convention Centre, Penang**

Time	Topics	Speaker
Sexual Function/Dysfunction		
1205 - 1220	Sexual Dysfunction in Patients with Exstrophy/ epispadias	Lim Li Yi
1220 - 1235	Epispadias Repair: Video Anatomy	Desmond Ling Chung Wei
1235 - 1245	Q&A	
1245 - 1345	**Lunch Symposium** By GSK	
1400 - 1500	BPE Minimal Invasive Surgical Therapy (MIST) Workshop	Lo Ka Lun

MUA-NAUS
Residents Session

Moderators:
Bhojraj Luitel (NAUS)
William Ong (MUA)

23rd November 2024

8:30 - 10.00 am

Function Room 7,
Setia SPICE Convention Centre, Penang

8.30 – 8.40 am
Opening remarks
- Mahesh Bahadur Adhikari, President NAUS

8.40 – 8.55 am
Laser and Radiation Safety in Endourology
- Shailesh Maharjan

8.55 – 9.10 am
PCNL: Still Relevant in the Age of RIRS?
- Kevin Chang

9.10 – 9.25 am
Genitourinary Tuberculosis: Challenges and Best Practices
- Nirmal Prasad Shah

9.25 – 9.40 am
AI 101 for Urology Residents
- Kenny Tee

9.40 – 9.50 am
Q & A

Closing remarks

VIATRIS CELEBRATES 25 YEARS OF VIAGRA®

The little blue pill celebrates its silver jubilee[1]

VIAGRA® delivers **grade 4 erections** to some men with ED, regardless of baseline hardness.[2]

The **tolerability** of VIAGRA® has been demonstrated in a wide range of patients with **ED and comorbid conditions.**[3]

In the **25 years** since VIAGRA® was first approved in **1998**[3]

VIAGRA® was the **first Food and Drug Administration (FDA)-approved** oral medication indicated for the treatment of ED and its approval was based on **21 clinical trials** involving nearly **4,500** men with ED.[1]

A vast amount of clinical research supports the efficacy and safety of VIAGRA®—including more than **136 trials conducted** with more than **23,000 patients** globally.[1]

Post-marketing surveillance provides an **ongoing track record** in "real-world" patients after product launch.[4]

*US FDA approval was in 1998 and Malaysia approval was in 1999.

References:
1. Goldstein I, Burnett AL, Rosen RC, *et al*. The serendipitous story of sildenafil: an unexpected oral therapy for erectile dysfunction. *Sex Med Rev*. 2019;7(1):115-128. **2.** Kadioglu A, Grohmann W, Depko A, *et al*. Quality of erections in men treated with flexible-dose sildenafil for erectile dysfunction: multicenter trial with a double-blind, randomized, placebo-controlled phase and an open-label phase. *J Sex Med*. 2008;5:726-734. **3.** Giuliano F, Jackson G, Montorsi F, *et al*. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. *Int J Clin Pract*. 2010;64:240-255. **4.** VIAGRA® Malaysia Prescribing Information dated 14 March 2022.

VIAGRA® Abbreviated Prescribing Information
API-VIAGRA-0322
Reference: CLD Viagra dated 14 March 2022
Full prescribing information is available upon request.

Viatris Sdn.Bhd. Reg. No: 201801018158 (1280174-H) 15-03 & 15-04, Level 15, Imazium No. 8 Jalan SS 21/37, Damansara Uptown 47400, Petaling Jaya, Selangor, Malaysia.

For Healthcare Professionals Only.

VIATRIS

FAUA Trainee Session *for* MUC 2024

Date : 23rd November 2024
Time : 1000 - 1200
Venue : Function Room 7, Ground Mezzanine Floor, Setia SPICE Convention Centre, Penang

Aim : To update trainees on regional practices as well as sharing on common challenges faced by up and coming urologists

Proposed program will be 7 short sessions on a multitude of topics. Each session will be 15 minutes each. 12 minutes for the talk and 3 minutes for Q&A.

Moderator : Zainal Adwin Zainal Abiddin

Time	Topic	Presenter
1000 - 1015	Introduction to FAUA and Trainee Session	Secretary General of FAUA
1015 - 1030	Starting My Own Urology Practice	Chhy Voreak
1030 - 1045	Work-Life Balance; Does it exist?	Watsapfon
1045 - 1100	Fellowship Training; Necessity or Optional?	Aizat Sabri Illias
1100 - 1115	Update on Real World Staging Methods for Prostate Cancer	Albert Ciam
1115 - 1130	Reconstructive Urologic Surgery; Access and Interest	Maria Immanuel
1130 - 1145	Flexible & Navigable Suction Ureteral Sheaths ; Ready for Primetime?	Joshua Tung
1145 - 1200	Laparoscopic Surgery in Cambodia ; My experience	Heng Oudam
1200	Group Photo and Quick Network Session	

Ural®
Effervescent Granules

DISSOLVES YOUR URIC ACID STONES

- **Helps to reduce and prevent the crystallization of uric acids[1]**
- **Helps to increase the solubility of uric acid stones[1]**

SUGAR FREE

LEMON FLAVOURED

MADE IN AUSTRALIA

Reference: 1. Ural® Malaysia PI, Apr 2022.

SCAN THE QR CODE FOR URAL® FULL PRESCRIBING INFORMATION (PI):

Information in full PI is accurate at the date and time of display. Please contact Abbott Sales Representative for the latest PI.

FOR HEALTHCARE PROFESSIONALS ONLY

ABBOTT LABORATORIES (M) SDN BHD 198701004889 (163560-X)
27-02, Level 27, Imazium, No. 8, Jalan SS 21/37, Damansara Uptown,
47400 Petaling Jaya, Selangor Darul Ehsan, Malaysia.
Tel: 03-7988 7000

Abbott Ref ID: MAL2331739 OCT 2024

Abbott

Invited Speakers Profile (LOCAL)



Alex Khoo Cheen Hoe

Consultant Nuclear Medicine Physician
Adventist Nuclear Medicine Centre

Dr Alex Khoo Cheen Hoe graduated from University of Malaysia and pursued his postgraduate studies in nuclear medicine from University of Science Malaysia. He is board-certified fellow of the Asian Nuclear Medicine Board as well as the European Board of Nuclear Medicine. He is currently working at Adventist Nuclear Medicine Centre which is the first private center with comprehensive nuclear medicine center in Northern Malaysia. Adventist Nuclear Medicine Center is currently the only private hospital in Northern Malaysia providing the Ga-68 PSMA PET-CT studies and have started PSMA therapy services.

Azilawati Hanim Binti Ghozali

Paediatric Nephrologist Hospital Pulau Pinang

MBBS Melaka Manipal Medical College 2008
Doctor of Paediatric, UKM 2018
Paediatric Nephrology Fellowship SickKids, Toronto, Canada
Special interest in pediatric kidney transplan

Ch'ng Ling Sing

Urologist
Hospital Sultanah Bahiyah, Alor Setar

Dr Ch'ng is a urologist working in Hospital Sultanah Bahiyah, Alor Setar. She graduated from The University of Melbourne, Australia in 2012 and completed an internship in The Northern Hospital, Victoria. She then returned to Malaysia and joined urology training in 2017. After completion of urological training with rotations to various public hospitals in Malaysia, she worked in the aforementioned hospital, a tertiary hospital for the past two years. She has an interest in Pediatric Urology and will pursue further training in the future

Chew Bee See

Consultant Pathologist and Uropathologist
Sunway Medical Centre, Suncity, Subang Jaya, Kuala Lumpur

Dr Chew Bee See obtained her medical degree, MBBS, from University of Dhaka and Master of Pathology from University of Kebangsaan Malaysia. She is an Anatomic Pathologist and had undergone urological sub-specialty pathology trainings under Ministry of Health, Malaysia. Currently she is the Consultant Pathologist and Uropathologist at Sunway Medical Centre, Suncity, Subang Jaya, Kuala Lumpur.

Dr Chew has a keen interest in medical education and research, she also enjoys working for non-governmental organizations. She is a Council member for International Academy of Pathology (IAP Malaysian Division) and the treasurer for The Chapter of Anatomy Pathology, College of Pathologists, Academy of Medicine Malaysia. She is a member of international and national academic bodies; a life member for College of Pathologists, Academy of Medicine Malaysia, Malaysian Society of Cytology (MS0C), International Academy of Pathology (IAP Malaysian Division), International Society of Urological Pathology (ISUP), Genitourinary Pathology Society (GUPS) and British Association of Urological Pathologist (BAUP). She is also a panel member for ISO15189 laboratory accreditation under Department of Standards Malaysia (DSM).

Invited Speakers Profile
(LOCAL)

Clarence Lei Chang Moh
Consultant Urologist
Normah Medical Centre, Kuching, Sarawak

Dr. Clarence Lei graduated from the University of Malaya in 1981 and earned his Fellowship with the Royal College of Physicians & Surgeons of Glasgow in 1986. He trained at the Institute of Urology, Great Ormond Street Hospital, Edinburgh Western GH, and Nuffield Transplantation Surgical Unit. He holds FRCS Urology and Fellow of European Board of Urology and a postgraduate diploma in Medical Education from the University of Dundee. He was a urologist and deputy head at KL General Hospital, founding head of surgery at University Malaysia Sarawak (1995–1998), and has served as MUA President and an examiner since 2000. Dr. Lei is an adjunct professor and consultant to Normah Hospital, Sarawak GH, Sarawak Heart Centre & HKL.

Datesh Daneswar
Consultant Urologist
Prince Court Medical Centre, Kuala Lumpur

Mr Datesh Daneshwar is a consultant urologist and the head of department at the Prince Court Medical Centre. He has a fellowship in robotic surgery and uro oncology. He has special interest in mens health and has done some work under David Ralph in UCL London. Over the years he has had a keen determination to find a way to cure ED rather than just treat it
medically. His has published work on his experience with Low intensity shockwave therapy for ED and prostatitis.

He is also recognised by Stortz medical as one of their KOL for the use of Shockwave therapy in treating ED in this region.

Desmond Ling Chung Wei
Urology Trainee Year 2
Department of Surgery, Urology Division
University Malay Medical Centre

Qualification : MBBS University Malaya 2011–2016,
MRCS 2019

George Lee
Consultant Urologist
Gleneagles Hospital Kuala Lumpur

Dr George Lee Eng Geap completed his basic degree in Pharmacology from Cambridge University, and medical degree at Addenbrookes' Clinical School of Medicine in Cambridge. Dr Lee pursued his Surgical Career in Oxford and his Urological training at Imperial College School of Medicine in London. He became a consultant Urologist in the United Kingdom, before he took on the position as the Associate Professor of Surgery at University Malaya, Kuala Lumpur. Professor George Lee is currently a clinical Associate Professor of Surgery at Monash University and Consultant Urological Surgeon from Gleneagles Kuala Lumpur.

Professor George Lee Basic research work was on the mechanism and the mutagenesis of receptors in exocytosis. His main clinical interests are in endourology, Prostate Diseases and Andrology. He published extensively in Biochemical Journal, BJUI and International Urology and Nephrology.

Invited Speakers Profile
(LOCAL)

Git Kah Ann

Consultant Urologist
Pantai Hospital Penang.

He graduated from University of Malaya, Kuala Lumpur in 1996 and obtained his Masters of Surgery from University Kebangsaan Malaysia in 2003 where he was the best candidate in the Masters Examination. He is a Malaysian Board Certified Urologist from 2008 and conferred the FRCS(Urol) of Glasgow. He spent a year on Melbourne, Australia (2008-2009) as a Clinical Fellow in Urology. He is also an academician in the Academy of Medicine Malaysia. Despite currently in private practice he has a keen interest in teaching and is a former Board Member of the Malaysian Board of Urology and appointed Honorary Consultant Urologist to the Department of Urology of Hospital Pulau Pinang. He is also an Organising Committee Advisor and Faculty of the Malaysian Urological Conferences and a faculty at the Malaysian Advanced Urology Courses. Since 2011, Dr. Git have organised and moderated the Endourology Night at the Malaysian Urological Conferences. He started the Penang Stone Course in 2010 and is now a popular Urology course in Malaysia. He has organised and performed several live workshops in Endourology both locally and abroad. With his keen interest, he is currently the Director of Endourology of the Malaysian Urological Association.

Kumarrapan Alagappan

MD (UCSI) MRCS (RCSI) FRCS (Urol) Glasgow
Urologist
Hospital Pulau Pinang

Obtained his medical degree from UCSI University in 2011 and completed post graduated training in Urology via the parallel pathway training under the Malaysian Board of Urology- Royal College of Physicians & Surgeons of Glasgow in 2021. Subsequently went to pursuit fellowship training in Uro-Oncology at The Queen Elizabeth Hospital, Adelaide.

He serves as a resident urologist in General Hospital Pulau Pinang. His primary interest are in urological malignancies particularly kidney and bladder. BPH and stone management also forms major bulk of the work.

He is a member of Malaysian Urological Association, Urology Association of Asia, European Association of Urology, American Urology Association.

L. Sivaneswaran

Consultant Urologist And Head Of Urology
Hospital Raja Permaisuri Bainun, Ipoh, Perak

Dr. L.Sivaneswaran is the consultant urologist and head of urology from Hospital Raja Permaisuri Bainun, Ipoh, Perak Malaysia.

He graduated from Melaka Manipal Medical University in 2005 and completed his masters of general surgery with University Malaya in 2014. He served as a general surgeon in Taiping before joining the urology program 2 years later.

He went on to complete his training under the Malaysian Board of Urology and secured his urology fellowship with the Royal College of Physicians and Surgeons, Glasgow in 2019. He later pursued a clinical urology fellowship at The Alfred, Melbourne in 2021.

Dr.Siva then returned to Malaysia in 2022 to serve in Ipoh as Perak state's 1st resident urologist. He has since setup the unit which also serves as a urology training centre. He has numerous publications to his name and has won many international accolades for research presentations. In 2023 he was awarded the Fellowship Ed Eundem and admitted as Fellow of the Royal College of Surgeons, Ireland for his decade long academic contributions to the college.

Dr.Siva is also the pioneer of prostate cancer focal therapy in Malaysia using HIFU with the largest case series in south east asia. He plans to expand the interest and services across the region, as part of the Asian Focal Therapy Society.

Invited Speakers Profile
(LOCAL)

Lim Li Yi
Urologist
Hospital Canselor Tuanku Muhriz UKM

Dr Lim graduated from University of New South Wales in 2008 and completed her general surgery training in UKM in 2018. She proceeded with her urology subspecialty training. After completion in 2022, she went to Taipei Tzu Chi hospital to pursue her special interest in paediatric urology. She is currently working as a Urologist at Hospital Canselor Tuanku Muhriz UKM.

Ngoo Kay Seong
Consultant Urologist
Tuanku Mizan Armed Forces Hospital
Kuala Lumpur

Dr. NGOO KAY SEONG is a Consultant Urologist from Tuanku Mizan Armed Forces Hospital, Kuala Lumpur, with an interest in endourology, uro-oncology (including hyperbaric medicine) and men's health. He graduated MBChB with Commendation from the University of Aberdeen, Scotland and went on to pursue his Master of Surgery (General Surgery) at the National University of Malaysia. His subspecialisation training in Urology under the Malaysian Board of Urology was undertaken at Selayang Hospital and the Institute of Urology and Nephrology at Kuala Lumpur Hospital. Subsequently, Dr Ngoo received the diploma of Fellowship in Urology from the Royal College of Physicians and Surgeons of Glasgow. He was also the recipient of the 2017 Young Urologist Fellowship from the Urological Association of Asia. In 2018, Dr Ngoo won the International Foundation Scholarship for Young Urologist in Asia to pursue a mini-Fellowship in Minimally Invasive Uro-oncology at Tottori University, Yonago, Japan.

He was the Scientific Committee member (Young Urologists' Session lead) of the 17th Urological Association of Asia (UAA) Congress 2019 held in Kuala Lumpur. Dr Ngoo was also the Deputy Chairman of the Malaysian Urology Research Consortium from 2019-2020. Latterly, he was appointed the Section Head for Health Awareness of the Malaysian Urological Foundation as well as the Secretary of the Malaysian Society of Andrology and the Study of Ageing Men (MSASAM). Dr Ngoo was also the Executive Committee Member (Youth Section) of the Malaysian Urological Association (2020-2022). In 2024, he was inducted as a Fellow of the Academy of Medicine Malaysia.

In addition, Dr Ngoo is currently involved as the first Malaysian Innovators Member of Societe Internationale d'Urologie (SIU). He had successfully co-organised the Prostate Unlimited Webinar in 2020 under the SIU and was invited to speak at the Royal College of Surgeons of Edinburgh International Webinar on Military, Humanitarian and Rural Surgery in 2021. In addition, Dr Ngoo was also invited to speak in various urological and general surgical meetings, as well as published a few papers and book chapters. He is an active member of the European Association of Urology, Malaysian Urological Association, MSASAM, SIU, UAA, international member of the Korean Urological Association and the International Surgical Society.

Invited Speakers Profile
(LOCAL)

Noor Ashani Md.yusoff

Senior Consultant Urologist and Head of Department
Department of Urology, Hospital Kuala Lumpur

Dr. Noor Ashani Md. Yusoff currently working as Senior Consultant Urologist and Head of Urology Department, Hospital Kuala Lumpur, Malaysia. He has been entrusted to be the Head of Urology Specialty in Ministry of Health Malaysia. He has been appointed as an Adjunct Professor at Hospital Sultan Azlan Shah UPM since year 2000. Currently he is also the President of Malaysia Urological Association (MUA).

He qualified as General Surgeon in 2002 after completed his Master of Surgery (General) at Universiti Kebangsaan Malaysia(UKM). He continue his training as Urologist under the auspice of Malaysia Board of Urology in collaboration with Ministry of Health Malaysia (MOH) and Malaysia Urological Association (MUA). And completed his urology training in 2007. He was conferred Diploma in Fellowship , FRCS (Urology)(Glasgow) in 2014.

His interest mainly in minimally invasive surgery particularly robotic assisted laparoscopic surgery. He started his robotic surgery training in 2004 under the supervision by Dato' Dr. Sahabudin Raja Mohamed, the pioneer of robotic surgery in Malaysia. His robotic surgery training continue at Yonsei Severance Hospital, Seoul, Korea in 2010 under the supervision of Dr. Khoo Hon Rha, the pioneer of robotic surgery in Korea.

He has performed more than 400 cases of Robotic Assisted Laparoscopic surgery, from RAL Radical Prostatectomy to RAL Retroperitoneal Lymph Nodes Dissection. He is the pioneer RAL RPLND in Malaysia and has the largest series in South East Asia. He has proctored more than 80 cases of Robotic Assisted Laparoscopic Surgery throughout Malaysia and has been invited to give several talks related to Robotic Assisted Surgery local. or internationally.

Nur Azreen Abdul Aziz

Hospital Selayang

Dedicated registered nurse that specializes in Urology Surgery for almost 14 years.

Urology Operation Theatre, Hospital Kuala Lumpur
9 August 2010 - 6 September 2024
Hospital Selayang
September 2024 – current

SKILLS
Surgical patient care
Organ Procurement Surgery (kidney)
Renal Transplant Surgery Pediatric Urology Surgery Robotic Surgery Urodynamic Study

RESPONSIBILITIES
Educate and guiding graduate nurse on peri operative practise
Coordinate with specialist and staff to prepare for the surgery
Counter Nurse In-Charge for arranging Operating Room Surgeries, staff and OR schedule

Poongkodi Nagappan

Consultant Urologist
Department of Urology, Kuala Lumpur Hospital

Dr Poongkodi Nagappan is a Consultant Urologist at Kuala Lumpur Hospital, Malaysia. She graduated from University Malaya in 1999, completed her surgical and urological training in Malaysia, before leaving for the Royal Manchester Children's Hospital to develop her interest in Paediatric Urology. Dr Poongkodi Nagappan is a Fellow of the Royal College of Physicians and Surgeons of Glasgow and Honorary Secretary of the Malaysian Urological Association

Invited Speakers Profile
(LOCAL)

Roger Anthony Idi
Consultant Urologist
Hospital Umum Sarawak

I was awarded a Doctorate in General Surgery by Universiti Kebangsaan Malaysia in 2016. I then served in Sibu Hospital as a General Surgeon before deciding to subspecialize in urology. I worked under the guidance of Dr Teh Guan Chou in Sarawak and Dato Dr Rohan Malek at Selayang Hospital from 2018 to 2021 before completing my fellowship in paediatric urology at the Great Ormond Street Hospital for Children, London under Professor Imran Mushtaq and Mr (Dr) Navroop Johal. At present, I am working as a consultant urologist at Hospital Umum Sarawak.

Shankaran Thevarajah
Consultant Urologist and Head of Department
Department of Urology
Hospital Queen Elizabeth

Dr Shankaran graduated from University of Malaya (UM) in 1999 and completed his general surgery training in UM in 2007. He later proceeded with his urology subspecialty training. After completion in 2013, he continued his fellowship in The Queen Elizabeth Hospital, Adelaide, SA. He is currently working a s a Urologist at Queen Elizabeth Hospital, Kota Kinabalu, Sabah.

Sritharan Subramaniam
Senior Consultant Urologist & Renal Transplant Surgeon
Island Hospital, Penang

Sun Kian Joo
Urology Trainees
Department of Urology
Hospital Queen Elizabeth, Sabah

MD (Charles University in Prague, Czech Republic) year 2015 under JPA scholarship
MRCS (Ireland) year 2019
HO and MO-ship in Queen Elizabeth Hospital, Kota Kinabalu, Sabah (April 2016 – December 2022)
2 years as Urology trainee in Queen Elizabeth Hospital, Kota Kinabalu, Sabah (January 2022 – December 2023)
Currently working as 3rd year Urology trainee under Sarawak General Hospital and Sarawak Heart Centre in Kuching

Suriaraj Karppaya
Urologist
Queen Elizabeth Hospital, Sabah

Dr Suriaraj Karppaya is a Urologist at Hospital Queen Elizabeth Sabah. He graduated from University of Malaya in 2011. He obtained the Membership of Royal College of Surgeons (MRCS) Edinburgh in 2016. He then completed his Urology training in 2021 obtaining the FRCS (Urol) Glasgow and Malaysian Board of Urology (MBU) certification.

He has recently completed a Fellowship in Bladder Cancer, Uro-Oncology and Robotic Surgery at the Western General Hospital, Edinburgh, United Kingdom

Syahril Anuar Bin Salauddin

Urologist
Hospital Tengku Ampuan Afzan, Kuantan, Pahang
MD (UKM), Doctor of General Surgery (UKM), FRCS Glasgow (Urology), Board of Urology (Malaysia)

Dr Syahril Anuar Bin Salauddin is a urologist at Hospital Tengku Ampuan Afzan (HTAA), Kuantan, Malaysia. He has worked as general surgeon since 2015 and used to be the Head of Surgical Department in Hospital Kuala Lipis, Pahang. Since 2017, he has been pursuing a subspeciality programme in Urology and certified with FRCS Glasgow (Urology) and Board of Urology (Malaysia). During the training period, he has participated in multiple local and international conferences including the 17th European Urology Residents Education Programme (EUREP) in 2019. Once completed, he actively involved as organising member for the Malaysian Urological Conference in 2022 and 2023. He represented Malaysia in the UAA Young Leadership Forum 2023 (formerly known as Young Urologist's Fellowship Program) held in conjunction with the 20th UAA Congress in Dubai, United Arab Emirates.

Dr Syahril Anuar Bin Salauddin has an interest in genitalia reconstructive surgery and is currently working under direct supervision from the experienced consultant reconstructive urologist in Malaysia, Dr Hamid Bin Hj Ghazali. He has several publications on this topic. Recently, he assisted renowned reconstructive urologists, Dr Pankaj Joshi from Kulkarni Reconstructive Urology Centre and Dr Faisal Alhajeri from Farwaniyah Hospital Kuwait, during the ISORU Live Urethroplasty Workshop 2023 in Universiti Putra Malaysia (UPM).

Syarah Zakaria

Urology Clinic
Hospital Kuala Lumpur
In Charge for Urology Paediatric Combined Clinic

Experience
2015-2017
Urology ward
Clinic Area

2012-2014
Diploma in Nursing Kubang Kerian

Tan Ai Lian

Dr Tan Ai Lian graduated from Chinese Medical University, Taiwan. She was trained in Internal Medicine in National Taiwan University Hospital before returning to Malaysia to serve the public sector.

Dr Tan received her clinical oncology training in Penang General Hospital before being admitted as Fellow by Royal College of Radiologists in Clinical Oncologist (London) in 2015. After that Dr. Tan continue her career in doing attachment in National Cancer Centre Singapore. Currently she is Clinical Oncologist in Penang General Hospital and is also the visiting oncologist in Bagan Specialist Centre.

Her special interest is in lung cancer and head and neck cancers. She is currently also actively involvement in several clinical trial in Penang General Hospital . Dr Tan also involved in teaching, she is a trainer in Malaysia Master Clinical Oncology Programme and Parallel Pathway Oncologist Training Programme.

Invited Speakers Profile
(LOCAL)

Tan Jin Rong
Urology Trainee
Department of Urology
Hospital Umum Sarawak, Kuchiing

MBBS from Melaka Manipal Medical College (MMMC), Malaysia - 2016
MRCS from Royal College of Ireland – 2020
Serve as HO in Hospital Pakar Sultanah Fatimah, Muar (December 2016 – December 2018)
MO in Hospital Bintulu, Sarawak (January 2019 – December 2020)
Urology Trainee Year 1 in Hospital Sultanah Aminah, Johor Bahru, Johor. (July 2021 – December 2022)
Currently working as 3rd year urology trainee in Hospital Umum Sarawak, Kuching since 2023
Actively involved in organizing prostate health campaign and Urology update.
Multiple publications in local and international journal.
Main interests are Uro Oncology and Endourology
Aim to expand the basic urology service to rural areas of Borneo.

Taniza Ahmad
Sister
OT Manager & Urology OT In-Charge Sister
Hospital Pulau Pinang

Taniza Ahmad has been a vital part of Hospital Pulau Pinang since 1999, leading the Urology OT since 2003. She holds a Diploma in Nursing and Post-Basic Certificate in Perioperative Nursing, specializing in urology surgeries. As a member of the Safe Surgery Safe Life Committee, Taniza is committed to enhancing patient safety. She has played a key role in organizing major workshops, including the Stone and HoLEP Workshops, and is a respected figure in perioperative care, known for her leadership and dedication to surgical excellence.

William Ong Lay Keat
Urologist
Hospital Sultanah Bahiyah, Alor Setar

Dr. William Ong is a consultant urologist practising at Hospital Sultanah Bahiyah, Alor Setar, Kedah. He holds an M.B.B.S. degree from Manipal University and is a member of the prestigious Royal College of Surgeons of Ireland (MRCS) and Fellowship Royal College Surgeons and Physicians of Glasgow Urology (FRCS). His clinical expertise was further honed through a one-year uro-oncology fellowship at the Queen Elizabeth Hospital in Adelaide. Dr. Ong's dedication to patient care is evident in his active involvement in the Global Interstitial Cystitis Bladder Pain Syndrome Society (GIBS). His service contributions have been recognized with numerous awards, including an Excellence Service Award from his alma mater.

Dr. Ong is passionate about teaching, and he actively engages in mentoring urology trainees, junior doctors as well as medical students. He led the clinical trial of low intensity shockwave therapy of erectile dysfunction in Penang General Hospital. His research endeavours have led to numerous publications in esteemed international journals like European Urology, World Journal of Urology, BJU International, and the Andrologia. Additionally, he serves as a reviewer for renowned journals such as Société Internationale d'Urologie Journal, Journal of International Medical Research, and BMJ Care Reports, contributing to the advancement of medical knowledge.

Wong Peng Shyan
Head of Infectious Diseases Unit
Hospital Pulau Pinang, Malaysia

Dato' Dr Wong Peng Shyan is currently the Head of Infectious Diseases Unit in Hospital Pulau Pinang, Malaysia. She graduated from the University of Malaya, Kuala Lumpur and obtained her MRCP (UK) in 2002. She did her Infectious Diseases training in Hospital Kuala Lumpur, Hospital Sungai Buloh, Royal Melbourne Hospital and Peter MacCallum Hospital, Australia. Her current interest is management of dengue and urological infections.

INTIMACY + SPONTANEITY
Daily Pill + Daily Benefits

Cialis® tadalafil

Why interrupt a spontaneous moment to pop a pill or pause to go to the bathroom?

BE READY[1]

Only Cialis 5mg once daily treats both ED and the frustrating signs and symptoms of Benign Prostatic Hyperplasia (BPH)[2]

PRESCRIBING INFORMATION

Scan QR code for MY Cialis 5mg PI

The prevalence of coexisting ED and BPH-LUTS is high, especially in older men, the possibility of a single medical therapy approved to treat both conditions is of clinical interest[3]

- **Cialis 5mg taken at approximately the same time each day**
- **With or without food[4]**
- **Without regard to timing of sexual activity because dosing and sexual activity would no longer need to be temporally linked[5]**

REFERENCES

1. Porst et al, European Urology 50(2006)351–359 2. EAU-Guidelines-on-Non-Neurogenic-Male-LUTS-2022 3. Egerdie et al J Sex Med 2012;9271–281 4. MY Cialis 5 mg _PI_EUSPC _28 Jan 2021_05 May 2021 5. Porst et al, J Sex Med 2008;5:2160–2169

ZP THERAPEUTICS
making healthcare more accessible

ZP Therapeutics (A division of Zuellig Pharma)
Zuellig Pharma Sdn Bhd 196001000352 (4013-D)
No. 15, Persiaran Pasak Bumi, Seksyen U8,
Perindustrian Bukit Jelutong,
40150 Shah Alam, Selangor Darul Ehsan, Malaysia.
T +60 3 5566 2288 I F +60 3 5566 2388
www.zuelligpharma.com

Malaysia Adverse events should be reported to zpmypv@zuelligpharma.com
Before prescribing, please refer to the full prescribing information.
For healthcare professionals only.

MY-PM-LILLY-CIALIS-POS-HCP-000002-04-2024

Invited Speakers Profile
(INTERNATIONAL)

AUSTRALIA

Marinelle Doctor
Urology Clinical Nurse Consultant, Nepean Hospital
Chair, NSW-ACT Section Australia and New Zealand Urological Nurses Society (ANZUNS)
Immediate Past Chair, Asian Urological Nursing Association (AUNA)

Rick Catterwell

Dr Rick Catterwell is an Australian-based health professional specializing in the field of Urology. With a commitment to patient care and a deep understanding of urological conditions, Dr Catterwell brings a wealth of knowledge and expertise to his practice.

Dr Catterwell received his medical degree and completed his specialized training in Urology. He has earned a reputation as a highly regarded Urologist, known for his dedication to improving the health and well-being of his patients. With a focus on providing personalized care, Dr Catterwell is dedicated to understanding each patient's unique needs and developing tailored treatment plans to achieve the best possible outcomes.

With a strong clinical background, Dr Catterwell has extensive experience in diagnosing and treating a wide range of urological conditions. These include, but are not limited to, urinary tract infections, kidney stones, prostate issues, bladder disorders, and urinary incontinence. Dr Catterwell utilizes the latest advancements in medical technology and treatment techniques to ensure his patients benefit from the most effective and up-to-date care available.

In addition to his clinical practice, Dr Catterwell is committed to continuing education and staying at the forefront of his field. He actively participates in conferences, seminars, and professional development opportunities to ensure he remains informed about the latest advancements in urological care. This dedication to ongoing learning allows Dr Catterwell to provide his patients with the highest standard of care, incorporating evidence-based practices into his treatment plans.

Invited Speakers Profile
(INTERNATIONAL)

China

Kai Zhang
Associate Consultant
Department of Urology
Beijing United Family Hospital

- Associate Consultant, Department of Urology, Beijing United Family Hospital
- PhD, Erasmus University Rotterdam, Netherlands
- Committee Member and Secretary-General, Genitourinary Cancer Holistic Rehabilitation (CACA-GUHR), China Anti-Cancer Association
- Committee Member, Engineering Group, Chinese Urological Association (CUA)
- Committee Member, Genital Oncology, China Anti-Cancer Association (CACA-GO)
- Member, Asian Urological Surgical Training and Education Group (AUSTEG)
- Published over 40 papers in SCI and core journals, with a highest impact factor of 18.6 (JAMA Surgery, 2023, First Author)

Zeng Guohua
Professor and Senior consultant in urology
Vice-director, The First Affiliated Hospital of Guangzhou Medical University (2012-present)

Professor Zeng Guohua is currently the Vice-President of The First Affiliated Hospital of Guangzhou Medical University, Chief of the Guangdong key lab of Urology, and Chief of Guangzhou Urology Research Institute. Director of certified fellowship program by Endourology Society. President of Guangdong provincial urological association, Associate member of EULIS.

He completed his Master of Urology training in 1992, and his PhD in Urology in 2000. Clinical endourology fellowship at UT Southwestern Medical Center at Dallas in 2007. As an experienced endourologist, he has finished more than 12000 endourological procedures including all kinds of PCNLs, rigid URS and RIRS procedures, and Uro-laparoscopic procedures.

Hong Kong

Lo Ka Lun
Consultant, Urology Team, New Territories East Cluster, Hong Kong
Service in Charge, Urology Team, Alice Ho Miu Ling Nethersole Hospital

Dr. Lo Ka Lun is currently the Honorary Clinical Associate Professor of the Chinese University of Hong Kong and Chairman of the Asian Prostate Federation.

His special interests are endoscopic enucleation of the prostate (BipoLEP / ThuFLEP / HOLEP), minimal invasive surgical therapy of BPH (Rezum / Urolift), systemic and MRI-USG fusion transperineal prostate biopsies, fiducial gold markers implantation, rectal spacer injection and en bloc resection of the bladder cancer.

For BipoLEP, he has performed live surgery demonstration and acted as a moderator of BipoLEP in SIU eGrand Rounds in 2018 and 2019 respectively.

For TPUS Bx, he has organized Hong Kong Freehand Transperineal Prostate Biopsy Workshop in the 10th Hong Kong Urology Sympo¬sium, 2018. During the Workshop, he also performed live demonstra¬tions of systemic and MRI-USG fusion transperineal prostate biopsies.

He actively participated in the international Urological Conferences and research publications. His research project won the Urological Contribution Award in Chinese Urological Association An¬nual Meeting, 2018. He also won the following Awards:

- Best Poster Display Award – Hospital Authority Convention of Hong Kong, 2019
- Video Presentation Award – 17th Urological Association of Asia Congress, Malaysia, 2019
- Most Appreciated Staff Award (North District Hospital) – 2019
- Most Appreciated Staff Award (North District Hospital) – 2020

Indonesia

I Wayan Yudiana

Division of Urology/Department of Surgery, Faculty of Medicine/Udayana University,
Sanglah General Hospital, Denpasar

2000 : Graduated in medical doctor at the University Udayana
2013 : Graduated in Urology at the University Airlangga
2020 : Urology-oncologist Consultant

Paksi Satyagraha

Consultant Urologist
Department of Urology Saiful Anwar General Hospital/ Faculty of Medicine Brawijaya University,
Malang Indonesia

Paksi Satyagraha, MD is an Indonesian Urologist specializing in Genitourinary Reconstruction and Endo urological treatment for stone disease. Graduated from Padjadjaran University Bandung for his medical doctor in 2004. He continued taking master's degree in microbiology and graduated in 2006. He started his urology residency program at Airlangga University Surabaya and finished at 2012. During his early years of career, his interest in genitourinary reconstruction and stone disease grew, he then attended post graduate training program at Kulkarni Center in Pune India to intensify his passion in urogenital reconstruction at the end of 2012. He has also visited several international centers of excellence as clinical observers in some countries. He is now working as Urologist at Department of Urology Saiful Anwar General Hospital/ Faculty of Medicine Brawijaya University, Malang Indonesia, and establishing one of few referral centers in genitourinary reconstruction surgery in Indonesia. In 2015, Indonesia Urology Association (InaUA) formed InaUA Section Genitourinary Reconstructive Surgery (InaGURS) and at the moment he is the chairman of the section. In 2017 and 2018 he was one of the founding faculty of two international reconstructive urology society: Asia-Pacific Society of Reconstructive and Andrology Surgeons (AP-SRUAS) and International Society of Reconstructive Urologist (ISORU). In 2019, he was appointed as the Board Member (BoD) of Genitourinary Reconstructive Society (GURS) and in 2023 he was also elected as the BoD of Societe Internationale d'Urologie (SIU). In September 2022, he was awarded as "Young Urologist" by Indonesian Urological Association (Ina-UA). He served as the general secretary of InaUA (2020-2023) and at the moment still serving as the general secretary of Federation ASEAN Urological Association (FAUA) from 2023-2026.

Invited Speakers Profile
(INTERNATIONAL)

India

Rajesh Taneja
Senior Consultant and Advisor Urology and Robotic surgery,
Indraprastha Apollo Hospital, New Delhi, India

- Mentor For Robotic surgery (Da Vinci)
- Mentor for Holmium Laser Enucleation of Prostate (HoLEP) to various universities in India and abroad
- Founder Chairman - Global Interstitial Cystitis Bladder Pain Society [GIBS]
- Conference President, GIBS Europe
- Former Chairman, Education Committee, ESSIC, (International Society for study of Bladder Pain Syndrome)
- Scientific Chairman for the 2016 Annual Meeting of European Society of Study of Interstitial Cystitis (ESSIC) Held at New Delhi, November 17-19, 2016

Uttam Mete
MS(Surg) DNB(Surg.) MCh(Urology), FRCSEd

Professor & Head, Department of Urology, PGIMER, Chandigarh.
Secretary, Urological Society of India

After completing his training in MS (Surgery) and MCh(Urology) both from PGIMER, Chandigarh, Dr. Uttam Mete had joined as faculty in the department of urology, in PGI, Chandigarh. He is actively involved in the activities of the Urological Society of India.. He has participated in debate, symposium and delivered lectures during during several conferences and workshops. He is the recipient of many fellowships and awards offered by USI, like G M Phadke travelling Fellowship, Member Travel Fellowship,Teacher Travel Fellowship etc. He has published several papers both in international & national journals. Laparoscopy, endourology, uro-oncology, renal transplantation, reconstructive surgery & urolithiasis are his main areas of interest. New passion for robotic surgery has widened his spectrum of expertise in urology. He has demonstrated live surgeries in many conferences and workshops.

Currently serving as Professor & Head in the prestigious Institute like PGI.

Japan

Akio Horiguchi
Professor of Urology
National Defense Medical College

Dr. Akio Horiguchi, Professor of Urology at the National Defense Medical College, specializes in reconstructive urology. He holds an MD from Keio University. Dr. Horiguchi directs the Trauma Reconstruction Department at his college and is the Education Director for Trauma, Emergency, and Reconstruction at the Japanese Urological Association. He has published extensively in peer-reviewed journals and received multiple awards, including the Best Presentation Award from the Japanese Urological Association. Dr. Horiguchi is recognized for his research in urethral stricture and urotrauma and is an active member of several international and Japanese urological associations.

Nepal

Bhojraj Luitel

Asst/Professor, Department of Urology and Kidney
Transplant Surgery, TU Teaching Hospital
Institute of Medicine, Tribhuvan University
Kathmandu, Nepal
General Secretary, NAU

Nepali Urologist with more than 10 years of experience in Endourology and renal transplantation.
Keen interest in Uro-oncology and Artificial Intelligence as applied to Urology
More than 40 Publications in National and Iner-national journals
Peer reviewer- International Journal of Urology and Indian Journal of Urology
Program Co-Ordinator- MCh (Urology) at TU Teaching Hospital
Currently Secretary General- Nepal Association of urological Surgeons(NAUS)
Council Member- SAARC Association of Urological Surgeons(SAUS)

Manish Man Pradhan

Assistant Professor
Department of Urology and kidney transplant surgery
TU Teaching Hospital, MMC, Institute of Medicine.

Nepalese Urologist and Kidney transplant surgeon with special interest in endourology and Kidney transplantation. He is involved in training of MCh urology residents in a premier academic institute of Nepal. Has been a part of in many research related to endourology – minimal access surgery at his institute and has been contributing actively in the renal transplantation program of his country. Currently an executive member of Nepal Association Urological surgeon as well as of young urology group of SAARC Association of Urological Surgeons, he is working to improve the exposure of young urologist via regional cooperation.

Sanjay Khadgi

Chairman, Khadgi Institute of Endourology
Lalitpur, Nepal

I have a broad base of general urological expertise, with a subspecialist interest in Endourology. My training was under Prof Zeng Guo Hua in Guangzhou, China who was the pioneer of mini-PCNL.

In 2005 I successfully brought this technique back to Nepal and have performed over 7,000 cases. My centre hosts visiting urologists from around the world who observe and learn this technique and have taken the skills home to benefit patients in their countries. I have also introduced laser enucleation of the prostate and performed over 650 cases so far.

I have been invited faculty at many international conferences and demonstrated live surgery at a number of meetings. I was awarded 'Best Poster Presentation' award at the First Conference of Experts in Stone Disease.

I enjoy meeting colleagues around the world who share my passion for endourology, exchanging ideas and advancing the knowledge base in this exciting subspeciality.

Invited Speakers Profile
(INTERNATIONAL)

Singapore

Daniel Yong
Deputy Head of Urology
Tan Tock Seng Hospital, Singapore

Dr Daniel Yong is currently the deputy head of urology at Tan Tock Seng Hospital, Singapore. He has completed fellowships at Duke University Hospital under Professors Glenn Preminger and David Albala, Okayama University Hospital under Professor Motoo Araki and most recently at Universitatsklinikum Hamburg-Eppendorf / Martini-Klinik (Germany) where he learnt advanced surgical techniques such as Neuro-SAFE from Prof Alexander Haese. He has a special interest in Uro-oncology and minimally invasive surgical techniques. He has published various peer-review papers and book chapters. He is the department head of research and is a member of the hospital research and innovation committee.

Tiong Ho Yee
Senior Consultant,
Department of Urology,
National University Hospital
Singapore

A/Prof Tiong Ho Yee graduated with Honours from the University of Nottingham, UK in 1997. He received his membership of the Royal College of Surgeons of England in 2001 after completing a General Surgical residency at the University of Leicester Hospital Systems, UK. During his subsequent Urology residency at National University Hospital (NUH), completed in 2006, A/Prof Tiong was awarded the Singapore Urological Association-European Board of Urology Book Prize in 2005 and 2007. He has been a Fellow of the Academy of Medicine, Singapore since 2007. As a recipient of the Ministry of Health Human Manpower Development Plan (HMDP) scholarship, A/Prof Tiong also completed a two-year clinical fellowship training in Kidney and Pancreas Transplantation at the Cleveland Clinic, Ohio, USA. He worked under the mentorship of the Glickman Urological and Kidney Institute faculty, ranked No.1 in the United States, to gain expertise in his current areas of interest – Kidney Surgery and Transplantation.

In 2009, he was certified and became a full member of the American Society of Transplant Surgeons. He is a certified transplant surgeon by the Ministry of Health, Singapore, serves on its advisory committee for transplantation, and is appointed as the Director of the National Pancreas Transplant Programme. At NUH, he is the Director for Kidney Surgery and Transplantation (Department of Urology), the Surgical Director for the Adult Kidney Transplantation Programme and Programme Director for Adult Pancreas Transplantation (National University Centre for Organ Transplantation), as well as the Programme Director of Urology Residency (National University Health System).
A/Prof Tiong aims to consistently lead in the field of kidney cancer surgery by performing minimally invasive kidney sparing surgery for localized cancers, as well as major open curative operations for advanced kidney cancers and transplantations. At NUH, he started the Da Vinci Robotic Kidney Surgery program with published outcomes for our kidney cancer patients using this surgical technique. With research and dedication, A/Prof Tiong believes in delivering patient-centric care and holistic management of his cancer and transplant patients.

Nuraishah Binte Zulkifle
Nurse Clinician and an Advanced Practice Nurse
Division of Palliative and Supportive Care (DSPC,)
National Cancer Centre Singapore (NCCS).

Nuraishah is a nursing lead for the education team at NCCS and DSPC, along with SingHealth Duke-NUS Supportive and Palliative Care Centre (SDSPCC), which collaborate with other palliative care specialist within the country towards improving palliative care education. She is involved in the teaching faculty for the Specialist Diploma in Palliative Care Nursing (SDPCN), Advanced Diploma in Palliative Care Nursing (ADPCN), and Lien Centre Palliative Care (LCPC). She is actively involved with voluntary overseas "train the trainer" trips with Asia Pacific Hospice Network (APHN) to help develop palliative care in countries like Bhutan and Jakarta .

Taiwan



Allen W Chiu

Secretary General, Urological Association of Asia
Honorary Professor, Shin Kong Hospital
Honorary Consultant, Mackay Hospital
Board of Committee, Far Eastern Hospital
Chairman, Shin-Shin AI Clinic, Taiwan

Dr. Allen Chiu graduated from National Yang-Ming University (1984) in Taiwan. He got Ph. D. from the Clinical Research Institute in his Alumni School (1996). He became the staff of Urology, Taipei Veterans General Hospital (the main teaching hospital of the medical school), after his residency in 1989. He was the clinical fellow in Boston University Hospital and the research fellow in the physiological laboratory of Boston University, USA from 1993 - 1994. He became the Chief, Department of Urology in Chi-Mei Medical Center in Tainan, Taiwan. He was later promoted as the Chief, Department of Research, in Chi Mei Hospital, and later to the Director of Chung-Xiao Hospital, Deputy Superintendent of Academy in Taipei City Union Hospital, Commissioner of Health - Taipei City government, Deputy Mayor of Taipei City Government, Dean of the School of Medicine (National Yang-Ming University), Superintendent, Taipei City Hospital. He was the President of Urological Association of Asia (UAA - 2012), Chairman of World Congress of EndoUrology (2014). He is the current Secretary General of UAA (2014 - 2026), Honorary Professor in Shin-Kong Hospital, Honorary Member of Japan Urological Association (JUA), Honorary Member of European Association of Europe (EAU). He was elected in the Advisory Board of Eastern Far Eastern Hospital and the Honorary Consultant of Mackay Memorial Hospital. He has held more than 40 workshops and symposia in Asian Pacific region. He published more than 200 articles in internationally renowned journals, 8 books and chapters. He gave more than 400 speeches in international conferences. He has many patents and awards, he won the Essay Contest, in World Congress of Urology 1996, he got the 2011 World Chinese Urology - Outstanding Award, the Highest Rank Award in Ministry of Health, (2011), Highest Rank Award from Executive Yuan of Taiwan (2014) and the Presidential Citation Award of American Urological Association (2017). He has trained more than 40 clinical fellows from all over the world. He is the first surgeon performed laparoscopic nephrectomy in Taiwan, the first laparoscopic radical cystectomy in Asian His major interest is in endourology, uro-oncology and Robotic assisted surgery in Urology, AI and Surgery and Medical Education.

Lin, Po-Hung

Department of Urology, Chang Gung Memorial Hospital, Linkou Branch.
No. 5, Fuxing St. Guishan Dist., Taoyuan City 333, Taiwan

Dr. Po-Hung Lin obtained his Doctor of Medicine degree from Taipei Medical University, Taiwan in 2005 and PhD in Clinical Medical Science from Chang Gung University in 2024. He is currently the assistant professor of the Department of Urology in Chang Gung Memorial Hospital, Linkou Branch. His subspecialty is uro-oncology, and expertise fields including laparoscopic and robotic surgeries, open surgery for complex urological diseases, as well as systemic treatments for advanced urological cancers. He also devoted himself to clinical and basic research for urological science and contributed to more than 40 peer-reviewed papers.

Invited Speakers Profile
(INTERNATIONAL)

Thailand

Tanan Bejrananda
Instructor in the Urology Unit,
Department of Surgery, Faculty of Medicine,
Prince of Songkla University
Thailand

Dr. Tanan Bejrananda, MD, PhD, is an Instructor in the Urology Unit, Department of Surgery, Faculty of Medicine, Prince of Songkla University. He completed his PhD in Health Sciences at Prince of Songkla University and has a fellowship in robotic urology from Fujita Health University, Japan. His areas of expertise include urologic oncology, robotic surgery, and minimally invasive urology. Dr. Bejrananda has numerous publications in the field, focusing on prostate and bladder cancer, and has contributed significantly to advancing urologic surgical techniques.

United Arab Emirates

Ranjith Ramasamy

Dr. Ranjith Ramasamy is a renowned reproductive urologist specializing in male fertility and sexual dysfunction. With extensive experience in the USA, he currently practices at Jumeirah American Clinic and First IVF in Dubai. Dr. Ramasamy has made significant contributions to the field of male reproductive health through his research, clinical work, and leadership roles with over 500 peer-reviewed publications. He serves on the editorial boards of several prestigious journals, and has completed a term as associate editor for Fertility and Sterility. His expertise includes managing complex cases of azoospermia, erectile dysfunction, and innovative fertility preservation techniques. Dr. Ramasamy is also actively involved in clinical trials and collaborations aimed at advancing reproductive technologies and improving patient outcomes

United Kingdom

Axel Bex
Clinical Lead of the Specialist Centre for Kidney Cancer
Royal Free Hospital London.

Axel Bex is Clinical Lead of the Specialist Centre for Kidney Cancer at the Royal Free Hospital London and Honorary Associate Professor at UCL Division of Surgical and Interventional Science. He is affiliated with the Netherlands Cancer Institute, Amsterdam, The Netherlands where he worked for 20 years as urologic surgeon. After receiving his MD degree at the University of Aachen, Germany in 1990 he followed his training at the Department of Urology, University of Essen Medical School and West German Comprehensive Cancer Centre. He was licensed as urologic surgeon in 1996. Subsequently, he specialized further in genitourinary oncology. His research impacted on clinical practice and kidney cancer guidelines of the European Association of Urology (EAU). He is in the steering committee of a variety of international clinical trials with practice changing potential and chairs the Genitourinary group of the European Organization of Research and Treatment of Cancer (EORTC). Axel Bex is involved in the scientific committees of the annual conferences of ESMO, the European Multidisciplinary Conference of Urological Cancers (EMUC), the Kidney Cancer Association (KCA) and the EAU.

United Kingdom

Christopher Eden

London Bridge Hospital, London, UK

As a surgical trainee, Professor Christopher Eden became a pioneer of laparoscopy urological surgery and has not stopped innovating since, performing the UK's first laparoscopic pyeloplasty in 1994, first laparoscopic radical prostatectomy in 2000, first laparoscopic radical cystectomy in 2001, first robotic Retzius-sparing radical prostatectomy in 2016 and first laparoscopic Retzius-sparing radical prostatectomy in 2016.

Professor Eden attended Guy's Hospital and King's College Hospital Medical Schools, achieving an MBBS in 1985 from the University of London after winning Surgery and Paediatric Prizes. He became a Fellow of the Royal College of Surgeons in 1995 and achieved a Master of Surgery degree from the University of London in 1997. He is currently Professor of Urology at the University of Surrey and Consultant Urologist at London Bridge Hospital, London, UK.

Professor Eden has specialised in the diagnosis and treatment of prostate cancer for more than two decades, has the UK's largest experience of minimal access radical prostatectomy, one of the world's largest personal series of minimal access urological operations at over 5,000 cases and has published more than 50 peer-reviewed papers on laparoscopic urology, 9 book chapters and a book

Max Cervellione

Paediatric Urologist
Royal Manchester Children's Hospital

I am a full time Paediatric Urologist at the Royal Manchester Children's Hospital, clinical lead for the Department, and I am nationally commissioned to provide the Bladder Exstrophy Service in Manchester which is one of only 2 centres in the UK for the treatment of this complex congenital malformation. I am also honorary clinical professor at the University of Manchester.

I have transformed the treatment of the exstrophy complex in the UK and Republic of Ireland with the introduction of new strategies of treatment following my clinical fellowship at John's Hopkins Hospital in 2009. In the last 15 years I hav introduced 3 new original surgical techniques for the treatment of exstrophy and epispadias. I have trained several international and national paediatric urology fellows. I have been the Lead for PGME at Royal Manchester Children's Hospital until 2018 and continue to be involved with postgraduate medical education at the University of Manchester and Nationally with the Royal College of Surgeons of Edinburgh.

I have published over 70 papers on basic science, experimental and clinical research in the main urological and paediatric surgical journals with over 800 citations, wrote 4 book chapters, and presented our work all around the world. I am a recognised international expert in the treatment of bladder exstrophy and varicocele. I am a regular reviewer for the Journal of Urology, British Journal of Urology and Journal of Paediatric Urology with over 100 reviews in the last 10 years and several editorial comments on major paediatric urological publications. I am an FRCS Urology examiner and trustee of the British Association of the Paediatric Urologists and I have participated to 3 charity missions in Vietnam since 2022 treating several cases of complicated bladder and cloacal exstrophy

United Kingdom

Mehwash Nadeem

Consultant Urologist
South Tees Hospitals NHS Foundation Trust,
Middlesbrough

Mehwash Nadeem specialises in conservative and surgical management of bladder dysfunction in both males and females. This includes: urinary incontinence, overactive bladder, chronic pelvic pain/ bladder pain syndrome, urinary tract infections and urinary tract fistula. She has particular interest in managing female urethral diverticulum, post prostatectomy incontinence and chronic urinary retention in females. She also offers sacral neuromodulation for overactive bladder and voiding dysfunction.

She has introduced a Complex UTI service in collaboration with functional urology specialist nurses sisters Jayne Morris-Laverick and Stephanie Bezemer, and microbiology consultants Dr Victoria McCune and Dr Igor Kubelka, with vision of expanding it to provide a regional level service. This clinic offers intravesical antibiotic and GAG replacement treatment for suitable patients.

She undertakes and supervises research in area of her clinical subspecialty interest. This includes male and female urinary incontinence and voiding dysfunction, bladder pain syndrome, urethral diverticulum, urinary tract fistulas and UTIs. She has presented in multiple national and international conferences, as well as published papers and book chapters on her area of interest.

She has a keen interest in education and training of medical students, trainees and the wider surgical teams.

Param Mariappan

MBBS(Hons), PhD, FRCS(Urol), FEBU, CBU(Mal).

Prof Param Mariappan is an internationally recognised key opinion leader and bladder cancer expert, who has been a consultant urological surgeon in Edinburghfor almost 20 years.

Having performed over 900 cystectomies and 6000 TURBTs, he is one of the UKs most experienced surgeons and leads Edinburgh's bladder cancer surgical service with a focus on effectiveness and efficiency in patient-centred care. Param plays a leading role in the development and continuation of the Scottish QPI programme for bladder cancer and designed the Scot BC Quality OPS project. He has published widely (h-index 32), featuring in some seminal work and has been PI for several clinical trials. Param sits on the EAU guideline panels for NMIBC, MIBC and UTUC; and is a core committee member of the International Bladder Cancer Group (IBCG). Outside work, Param is a keen 6 handicap golfer.

Simon Choong

Consultant Urologist
St John & St Elizabeth Hospital London

Mr Simon Choong undertook his medical school and postgraduate urological training at University College Hospital, London. He was appointed to lead the stone and endourology unit at University College London Hospitals in 2002. The unit manages complex urinary tract stones and provides minimally invasive management of upper urinary tract transitional cell tumors, pelviureteric junction obstruction, complex ureteric strictures and kidney obstruction.

He carries out paediatric stone surgery at Great Ormond Street Hospital for children and runs national and international masterclasses in stones and endourological management. He was awarded a Hunterian Professorship by the Royal College of Surgeons of England in 2000 and the BAUS / BJU International Travelling Fellowship in 2001.

United States of America

Murugesan Manoharan

Chairman, Department of Urology
Baptist Health Miami Cancer Institute

Murugesan Manoharan, M.D., FRACS, is a surgical urologic oncologist and the chief of urologic oncology surgery at Miami Cancer Institute. Dr. Manoharan specializes in the treatment of genitourinary cancers, including bladder, kidney, prostate and testicular cancer. Dr. Manoharan also serves as the chairman of the Department of Urology at Baptist Health South Florida and a professor of urology at Herbert Wertheim College of Medicine, Florida International University. In 2022, the Abbhi Family Endowed Chair in Urologic Oncology was created to help Dr. Manoharan and the Institute conduct research and clinical trials to improve survival rates and quality of life for patients with bladder cancer.He joined Miami Cancer Institute from the Sylvester Comprehensive Cancer Center, where he served as one of the site disease group leaders for genitourinary cancers. He also practiced urology at Jackson Memorial Hospital and the Veterans Affairs Medical Center in Miami. Dr. Manoharan is a renowned leader in the treatment of prostate cancer, kidney cancer, bladder cancer and other urologic malignancies. He is an expert in minimally invasive surgery, including nerve sparing robotic prostatectomy, robotic kidney surgery, robotic bladder removal and neobladder reconstruction. Dr. Manoharan was one of the first urologists in the United States to perform robotic bladder removal surgery and reconstruction of neobladder using a Pfannenstiel incision. He also specializes in other minimally invasive ablative cancer procedures, such as high-intensity focused ultrasound (HIFU) therapy, cryotherapy and the NanoKnife procedure to treat prostate cancer. He has extensive experience training medical students, residents and oncology fellows. He has won numerous awards for his teaching and clinical excellence, as well as his research work. Dr. Manoharan's research interests include stem cell applications, biomarkers and cancer outcomes. He serves as an editorial reviewer for several scientific publications. He is also widely published in peer-reviewed medical journals and is an invited speaker at national and international scientific symposiums. Dr. Manoharan has authored more than 140 scientific articles and 15 textbook chapters and has presented papers and posters at more than 100 national and international meetings. He served as vice chairman and a member of the International Bladder Cancer Guidelines committee, organized by the WHO and Société Internationale d'Urologie.When he is not treating patients, Dr. Manoharan enjoys music and traveling.

The + in Bipolar Surgery

BPH and NMIBC Treatment with the PLASMA+ System

PLASMA+

Procedure-Oriented, Safe and Efficient Solution for All Needs in BPH & NMIBC



We Are Proud to Introduce Our Most Advanced Energy System Yet:

PLASMA+

Millions of patients worldwide have been successfully treated with the Olympus PLASMA system.* The underlying HF technology of PLASMA has been used and **proven for over 17 years**.

Now, with the **third generation** of bipolar technology, we have integrated the **latest knowledge, experience and innovation**. The system sets new standards in terms of **performance, treatment options, safety, cost and time efficiency.**

* Data on file, as of Dec. 2020

Contemporary Management of Non-metastatic Bladder Cancer

Param Mariappan
Consultant Urological Surgeon,
Director, Edinburgh Bladder Cancer Surgery (EBCS) @EdinSurg_BC
The University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, United Kingdom.

The Bladder Cancer space has witnessed several recent developments, encompassing diagnostics, drugs, definitions and even de-intensification. In contemporary patient- centred care, however, it is vital that these developments are complemented by established fundamentals, to ensure the evidence is effectively translated to clinical practice. We will take a pragmatic approach to exploring this necessary balance.

En-bloc Resection of Bladder Tumour - Is it a relevant approach?

Po-Hung Lin
Assistant Professor,
Department of Urology, Chang Gung Memorial Hospital, Linkou Branch

En-bloc transurethral resection of bladder tumor (en-bloc TURBT) is an emerging technique designed to improve the management of non-muscle invasive bladder cancer (NMIBC). Traditionally, TURBT is the standard procedure but often results in fragmentation of the tumor, which can compromise histopathological evaluation and increase the risk of tumor seeding and recurrence. In contrast, en-bloc TURBT aims to remove the tumor in one piece, along with its underlying muscle layer, facilitating better pathological assessment of tumor margins and depth of invasion.

This technique utilizes various energy sources, including monopolar, bipolar, thulium laser, or holmium laser, to achieve precise and controlled resection. En-bloc TURBT offers several potential benefits, such as reduced tumor fragmentation, lower recurrence rates, improved specimen quality, and enhanced safety due to less bleeding and bladder perforation risk. In addition, the clearer visualization of tumor margins can aid in more accurate staging and guide adjuvant treatment decisions.

Studies comparing en-bloc TURBT to conventional TURBT have demonstrated comparable or better outcomes in terms of oncological safety, recurrence-free survival, and complication rates. However, there are technical challenges, including a steeper learning curve and longer operative times. Despite these challenges, en-bloc TURBT has shown promise in improving NMIBC management by enhancing diagnostic accuracy and reducing recurrence risk, making it an attractive alternative to conventional TURBT. Some randomized controlled trials have revealed its benefit compared to traditional TURBT.

Embracing AI in Urolithiasis Management

Paksi Satyagraha[1,2]
1 Department of Urology, Faculty of Medicine Universitas Brawijaya, Saiful Anwar Hospital, Malang, Indonesia
2 SIU Board of Directors

The integration of artificial intelligence (AI) into the management of urolithiasis represents a transformative advancement in urological practice. Recent studies highlight the efficacy of AI technologies, particularly deep learning algorithms, in predicting urinary stone composition and enhancing diagnostic accuracy through imaging analysis. These AI applications facilitate the segmentation and classification of stones in imaging studies, which is crucial for optimizing surgical planning and improving patient outcomes. Moreover, AI's role extends to personalized medicine, where AI-driven chatbots assist patients in dietary management to prevent calcium oxalate stones, demonstrating the potential for real-world clinical applications.

The evolution of minimally invasive surgical techniques, such as percutaneous nephrolithotomy (PCNL) and ureteroscopy, has been significantly influenced by AI. These techniques are increasingly favored due to their effectiveness and reduced recovery times compared to traditional open surgeries. AI's predictive capabilities also enhance decision-making in surgical management, allowing for tailored approaches based on individual patient profiles and stone characteristics. Furthermore, the development of automated algorithms for stone volume determination via computed tomography (CT) exemplifies AI's potential to streamline clinical workflows and improve the precision of treatment strategies.

Despite the promising advancements, the global adoption of AI in urolithiasis management varies, with disparities noted between developed and developing regions. The integration of AI technologies necessitates ongoing research and investment to ensure equitable access and effective implementation across diverse healthcare settings. As AI continues to evolve, its applications in urolithiasis management are expected to expand, leading to enhanced diagnostic capabilities, improved treatment outcomes, and a more personalized approach to patient care.

Management of Azoospermia

Ranjith Ramasamy
Consultant Urologist, Jumeirah American Clinic and First IVF, Dubai

Azoospermia, the absence of sperm in the ejaculate, affects approximately 1% of the male population and 10-15% of infertile men. This condition is broadly categorized into obstructive and non-obstructive azoospermia, with distinct etiologies and management strategies for each. This talk will explore the diagnostic approach, including hormonal, genetic, and imaging assessments, as well as the latest advances in surgical and medical treatments. Emphasis will be placed on microsurgical sperm retrieval techniques, the role of adjunctive therapies, and novel developments in reproductive technology aimed at improving outcomes for men with azoospermia.

Restorative Treatments for Erectile Dysfunction

George Lee Eng Geap
Consultant Urologist, Gleneagles Hospital Kuala Lumpur

Current treatments for erectile dysfunction (ED) include oral medications, intra-cavernosal injections, and vacuum-assisted devices. Though these therapies work well for many, a subset of patients have contraindications or are unsatisfied with these options. Restorative therapies for ED are a new frontier of treatments focused on regenerating diseased tissue and providing a potential "cure" for ED. This includes treatments such as stem cell therapy (SCT), platelet rich plasma (PRP), and restorative related technologies like low-intensity shockwave therapy (LiSWT). Restorative therapies are a promising technology that represents a new frontier of treatment geared towards reversing disease pathology rather than just treating symptoms. However, current published clinical studies are limited. Future work needs to be adequately powered, multi-center, randomized, sham/ placebo-controlled trials in well-characterized patient populations to ensure safety and demonstrate efficacy. Until these studies are done, restorative therapies should be reserved for clinical trials and not offered in routine clinical practice

Predicting Patient Outcomes after Robotic Surgery and Automating Skills Assessment

Christopher Eden
Professor of Urology, University of Surrey
Consultant Urologist, London Bridge Hospital, London

- AI is already here & is likely to be increasingly important in medicine & surgery.
- Aptitude testing is likely to allow better selection of trainee surgeons.
- Surgical training has become increasingly modular but for the first time, surgical skill outputs can be digitised and quantified to monitor progression.
- Standardised surgical training is likely to produce standardised surgical outcomes and hopefully better patient satisfaction.

Radical Therapy in Oligometastatic Prostate Cancer

Daniel Yong
Deputy Head of Urology, Tan Tock Seng Hospital, Singapore

Introduction
Androgen therapy has been the mainstay of treatment in metastatic prostate cancer. However, there is increasing evidence for radical treatment of the primary tumor in de novo metastatic disease.

Methods
A review of, HORRAD trial, STAMPEDE trial was conducted to determine the role of radiotherapy. Review of Saouli et al. metanalysis on the role of radical prostatectomy in the management of oligometastatic prostate cancer was also performed.

Results
HORRAD trial showed a significant improvement in PSA progression for radiotherapy with ADT compared to ADT alone. STAMPEDE trial confirmed that overall survival benefit was found in the low volume group (by CHAARTERED criteria). However, there is insufficient evidence to recommend radical prostatectomy in oligometastatic prostate cancer disease.

Conclusion
Radiotherapy should be offered to patient with oligometastatic prostate cancer. However, the role of radical prostatectomy is not established and should only be offered in a clinical trial setting.

Can PSMA-based PET-CT Be Used in the Diagnosis of Prostate Cancer?

[Catapult PSMA PET imaging into forefront diagnosis of Prostate cancer]

Alex Khoo Cheen Hoe
Consultant Nuclear Medicine Physician, Penang Adventist Hospital

Prostate-specific membrane antigen (PSMA)-based PET-CT imaging is now the preferred choice in staging prostate cancer. PSMA PET-CT has been found to have superior sensitivity and specificity compared to conventional imaging modalities. It is able to detect disease at lower prostate-specific antigen (PSA) levels than traditional imaging techniques; potentially leading to improved patient outcomes. Prostate biopsies are invasive and may yield false negative result depending on the methods used. Multiple studies on PSMA-based PET in the initial diagnosis of prostate cancer have shown promising results. The lecture will discuss the results and incorporating PSMA-based PET in diagnosis of prostate cancer in daily practice.

Management of Short Bulbar Urethral Stricture: When to transect and when not to transect

Professor Dr. Akio Horiguchi
Professor of Urology, National Defense Medical College, Japan

Bulbar urethral strictures are the most common type of male urethral strictures across all age groups. Selecting the appropriate reconstructive technique, such as excision and primary anastomosis (EPA) or onlay augmentation urethroplasty, depends on the stricture's location and length. Managing short bulbar urethral stricture requires a nuanced approach to determine when to transect and when not to transect the urethra. EPA is a well-established procedure with an excellent long-term success rate exceeding 90%. However, circumferential transection of the corpus spongiosum may not always be necessary, especially for non-traumatic strictures with minimal spongiofibrosis. Histological analysis reveals that non-traumatic strictures often have less extensive scar tissue compared to traumatic strictures, which require circumferential excision. While EPA is efficacious, it can lead to postoperative complications, including sexual dysfunction, presumably due to urethral transection. Non-transecting EPA techniques, developed by Dr. Jordan and further refined by Dr. Andrich and Dr. Mundy, offer a solution that preserves spongiosum tissue and reduces the risk of such complications without compromising success rates. Comparative studies show that non-transecting EPA achieves similar surgical success while minimizing sexual dysfunction. We, therefore, currently select the treatment for short bulbar urethral strictures as follows: EPA for traumatic strictures with dense spongiofibrosis and non-transecting EPA for non-traumatic strictures with minimal spongiofibrosis. This strategic approach ensures optimal outcomes and reduced risk of complications. EPA remains the gold standard treatment for traumatic bulbar urethral strictures, while non-transecting techniques are advocated for non-traumatic cases.

Reconstruction for Posterior Urethral Stricture due to PFU

Paksi Satyagraha[1,2]
1 Department of Urology, Faculty of Medicine Universitas Brawijaya, Saiful Anwar Hospital, Malang, Indonesia
2 SIU Board of Directors

Pelvic Fracture Urethral Injury (PFUI) represents a major clinical challenge, frequently resulting in complications such as urethral stricture, urinary incontinence, and sexual dysfunction. This injury commonly arises from shearing forces applied to the urethra during pelvic trauma. Accurate diagnosis is essential and relies on clinical assessment combined with imaging modalities such as retrograde urethrogram (RUG) for the initial evaluation. In more complex cases, Bipolar Voiding Cysto-Urethrography (BVCUG) or pelvic MRI may be employed to assess the location, length, and complexity of the stricture.

The management of Pelvic Fracture Urethral Injury (PFUI) depends on the severity of the injury and can range from suprapubic catheterization (SPC) with observation to delayed urethral reconstruction. In recent years, the use of minimally invasive techniques such as Primary Endoscopic Realignment (PER) has remained controversial due to inconsistent outcomes when compared to delayed urethral repair following SPC. Despite this, Excision and Primary Anastomosis (EPA) Urethroplasty continues to be the gold standard for PFUI treatment. Surgeons performing this procedure must ensure tension-free anastomosis and meticulous excision of scar tissue. This surgical objective can be achieved using perineal, extended perineal, or abdominal approaches. Early detection and appropriate intervention are essential for reducing long-term complications and optimizing patient outcomes.

The rising incidence of Pelvic Fracture Urethral Injuries has highlighted the need for advanced surgical techniques to effectively restore both urinary function and anatomical integrity. Recent advancements in surgical training and resource availability have significantly improved patient outcomes, while multidisciplinary collaboration has become increasingly prevalent, contributing to enhanced patient care. Furthermore, ongoing research and public awareness efforts are addressing the long-term effects of urethral injuries, promoting improved recovery strategies.

Surgical Modalities for Correction of Penile Paraffinoma

Syahril Anuar Bin Salauddin
Consultant Urologist, Department of Urology, Hospital Tengku Ampuan Afzan

Penile paraffinoma is described as abnormal tissue growth around the penis as a result of inappropriate injection of soluble foreign body into the penile skin. This method of penile augmentation is common in young adults around Southeast Asian Countries and usually performed by nonmedical personal. The patient presented with multiple symptoms, mainly a painful erection and ulcerated mass. Surgical treatment remains the treatment of choice for this disease, but no single standard technique has been proposed. In general, the type of surgical correction is divided into 3 categories: simple circumcision, using free skin graft and using scrotal skin flap. The skin graft is further divided into a split skin graft and a full-thickness skin graft. A few different techniques were reported regarding have scrotal skin flaps. Based on multiple literatures, the outcome of each surgical modality is described in this presentation.

Penile Prosthesis

Ranjith Ramasamy
Consultant Urologist, Jumeirah American Clinic and First IVF, Dubai

Penile prosthesis implantation remains a highly effective and reliable treatment for men with medically refractory erectile dysfunction. However, achieving optimal outcomes requires a deep understanding of the technical nuances and potential complications associated with the procedure. This talk will provide a comprehensive overview of "tips and tricks" to enhance surgical success, minimize complications, and improve patient satisfaction. Key topics will include preoperative planning, choosing the appropriate prosthesis, advanced surgical techniques for challenging cases such as Peyronie's disease or prior pelvic surgery, and postoperative management strategies. Special focus will be given to troubleshooting intraoperative and postoperative issues, as well as innovations in prosthesis technology.

Small Renal Mass Ablation

Tanan Bejrananda
Instructor in the Urology Unit, Department of Surgery, Faculty of Medicine, Prince of Songkla University.

This presentation explores the role of thermal ablation, including radiofrequency, microwave, and cryoablation, as a minimally invasive treatment for small renal masses (SRMs), particularly renal cell carcinoma (RCC) under 4 cm. It discusses patient and tumor selection criteria, ablation techniques, and outcomes, comparing the effectiveness and safety of ablation versus surgery. The session will include case studies demonstrating real-world applications and follow-up imaging, highlighting ablation's role in preserving renal function with fewer complications. Concluding with guidelines on follow-up care, the talk emphasizes ablation's potential for patients unsuitable for surgery.

Artificial Intelligence in Interstitial Cystitis /Bladder Pain Syndrome

Rajesh Taneja
Senior Consultant and Advisor
Urology and Robotic Surgery
Indraprastha Apollo hospitals, New Delhi India

Artificial Intelligence has become a part of our day-to-day life even before we realized it was coming in. The prompt on the smart phone, the autocorrect, is a simple example of artificial intelligence that has cropped into our lives. Medicine has not been left behind! Artificial intelligence (AI) driven algorithms have become a boon to pathologist and radiologists as they can increase the speed as well as precision in reporting.

Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a clinical disease entity, including a heterogenous set of patients. AI has been used in various aspects of IC /BPS and the data is being generated every single day, which is going to be used in deep machine learning. The confusion in taxonomy of the various apparently similar but diverse conditions under the umbrella term IC/BPS is more than obvious. Thus, the first step is recognizing this fact and streamlining the terminology, so that data to be used in AI could be correctly and uniformly utilized.

Incidence of Hunner's lesion (HL) is so varied in various series that it is possible that some workers are underdiagnosing the condition while others are over diagnosing. AI has been used for diagnosis of HL. Takuya et all (2022) published their work on application of AI in diagnosing the HL with mean sensitivity of 81.9% and specificity of 85.2% in the test dataset. However they do caution the need for further data input deep learning to reach a fool proof method as of now.

Eun et al (2021) designed a wearable smart band device that could recognize urination time and spacing based on patient-specific posture and consistent posture changes. They built a urination patient management system based on this device. The trial was very informative and had shown a high average accuracy of 95.8%, demonstrating the soundness of the proposed algorithm.

Electronic nose also known as eNose, is a device which can pick up the presence of various volatile compounds in voided urine. It is quite evident that these could serve as biomarkers for the diseases like UTI, IBS, and IC/BPS also . Afonso et al(2022) a metanalysis on the pooled data of the various volatile urinary solutes and found an accuracy of 84%. As of now it is just a beginning and more research is required to identify the specific urinary volatile 'biomarkers' for various subclasses of IC /BPS. Chancellor and Laura(2021 published their initial work on the collection of data on excretion of urinary cytokines, namely, GRO/CXCL1, interleukin [IL]-6, and IL-8. They routed their data through machine learning and arrived at some interesting data. This is a step towards use of high volume data being analysed by AI to be evaluated for possibility of a useful biomarker. Machine learning is far superior to humans when it comes to analysing data as shown by Cho et al (2023),while analysing the intravesical drug delivery system involving microbubbles and their membranes.

Akshay et al(2024) applied Machine learning algorithm on the transcriptome data obtained from the bladder biopsies of patients of IC/BPS, detrusor overactivity (DO), BPH and controls. They identified 13 candidate genes capable of differentiating DO from IC BPS. This data was matched with a large cohort of control population using quantitative polymerase chain reaction (QPCR)and run through supervised and unsupervised ML algorithm. A Three-mRNA signature TPPP3, FAT1, and NCALD, emerged as a robust classifier for non-ulcerative BPS. Thus an algorithm of ML has been generated which appears to be robust in differentiating patients with lower urinary tract dysfunction using the QPCR data of the target genes.

Ai is certainly going to make a big difference in the near future in clinical practice by suggesting a diagnosis based on the clinical and biomarker data, clinical progress on management, identification of flares and need for physician intervention, obviating the need for regular physical follow up unless required. An EMR with companion app for the patients would be a very useful practical outcome of the continuing research in this field of AI.

References

1. Takuya Iwaki, Yoshiyuki Akiyama, Hirokazu Nosato, Manami Kinjo, Aya Niimi, Satoru Taguchi, Yuta Yamada, Yusuke Sato, Taketo Kawai, Daisuke Yamada, Hidenori Sakanashi, Haruki Kume, Yukio Homma, Hiroshi Fukuhara, Deep Learning Models for Cystoscopic Recognition of Hunner Lesion in Interstitial Cystitis, European Urology Open Science, Volume 49,2023,Pages 44-50, SSN 2666-1683, https://doi.org/10.1016/j.euros.2022.12.012.
2. Eun SJ, Lee JY, Jung H, Kim KH. Personalized Urination Activity Management Based on an Intelligent System Using a Wearable Device. Int Neurourol J. 2021 Sep;25(3):229-235. doi: 10.5213/inj.2142276.138. Epub 2021 Sep 30. PMID: 34610716; PMCID: PMC8497735.
3. Afonso HAS, Farraia MV, Vieira MA, Cavaleiro Rufo J. Diagnosis of pathological conditions through electronic nose analysis of urine samples: a systematic review and meta-analysis. Porto Biomed J. 2022 Dec 1;7(6):e188. doi: 10.1097/j.pbj.0000000000000188. PMID: 37152083; PMCID: PMC10158878.
4. Chancellor, Michael B.,*; Lamb, Laura E.. Toward a Validated Diagnostic Test with Machine Learning Algorithm for Interstitial Cystitis. Urological Science 32(1):p 2-7, Jan–Mar 2021. | DOI: 10.4103/UROS.UROS_155_20
5. Cho Y, Park JM, Youn S. General Overview of Artificial Intelligence for Interstitial Cystitis in Urology. *Int Neurourol J.* 2023 Nov;27(Suppl 2):S64-72. doi: 10.5213/inj.2346294.147. Epub 2023 Nov 30. PMID: 38048820; PMCID: PMC10715831.
6. Akshay, A.; Besic, M.; Kuhn, A.; Burkhard, F.C.; Bigger-Allen, A.; Adam, R.M.; Monastyrskaya, K.; Hashemi Gheinani, A. Machine Learning-Based Classification of Transcriptome Signatures of Non-Ulcerative Bladder Pain Syndrome. *Int. J. Mol.* Sci. 2024, 25, 1568. https://doi.org/10.3390/ijms25031568

Update on Nodal Disease Management in Penile Cancer

I Wayan Yudiana
Department of Urology, Medical Faculty of Udayana University,
Prof. Dr. IGNG. Ngoerah Central Hospital, Denpasar-Bali

Penile cancer (SCC) is a rare disease, which only 0,4-0,6% of all men's malignant neoplasms in developed countries, but the incidence is higher in developing countries, including Indonesia, especially in regions where many people are uncircumcised with have poor hygiene. The peak incidence being in 6th decade; and several risk factors including pre-malignant lesions can actually be detected and prevented.

Diagnostic and staging of penile cancer are based on clinical features, imaging studies and histopathologic examination. The management of patients with penile cancer consist of primary tumors treatment and regional lymph node involvement. Primary tumors can be managed with penile organ-sparing treatment or penile amputation; and the management of regional lymph node involvement depend on patient's risk stratifications.

The presence and extent of regional lymph node metastasis (especially ILN) has been identified as the single most important prognostic indicator in determining long-term survival for patients with invasive penile SCC. It can be cured in over 80% of cases if the diagnosis and treatment can be early, but it will be a life-threatening disease when regional inguinal lymph nodes were involved. Management for regional lymph node metastasis depend on clinico- pathological risk factors (palpable or non-palpable, staging, grading, and lympho-vascular invasion of the primary tumors), biomarkers status as well as patient's nomogram.

Several surgical interventions such as DSNB, modified ILND, extended and salvage ILND as well as ileo-inguinal dissection can be performed with open, endoscopic or robotic surgery. To prevent complications, pre-operative preparation, intra-operative techniques and post-operative care should be carried out carefully. For patients with advanced disease (stage III and IV), adjuvant systemic therapy (chemotherapy, targeting therapy) as well as external radiation can be considered as part of multimodal treatment or multidisciplinary approach.

Keywords : penile cancer, inguinal lymph nodes involvement, inguinal lymph node dissection

Utilizing Social Media in Producing Research in the Current Era

William Ong Lay Keat
Urologist, Hospital Sultanag Bahiyah, Alor Setar

Social media has transformed from a communication medium to an essential tool in medical research amid swift technological advancement. It bridges the geographical distances, increases visibility of research, and promotes substantive scientific discussions among healthcare professionals. Real-time information sharing on social media platforms can build an online community where researchers can collaborate, critique, and offer dynamic feedback on urological studies.

Social media serves as a powerful tool for data collection, crowdsourcing, and peer review to conduct research. These platforms enable the acquisition of information from a diverse pool of input, allowing the researchers to rapidly gather data, obtain peer insights, and adapt methodologies towards addressing real-world needs.

The scope of dissemination of research via social media is massive. Social media has been crucial in boosting the reach and citation impact of research publications. Many studies has shown that articles shared online are more likely to be referenced, thereby amplifying their scientific and clinical significance. Additionally, social media provides a unique medium for public engagement, enabling urologists to bridge the gap between research and patient awareness. However, ethical considerations, such as upholding professional boundaries and protecting patient confidentiality, must be prioritized.

The integration of artificial intelligence with social media opens up exciting opportunities for predictive analytics, trend recognition, and content customization of the research. In conclusion, urologists are encouraged to embrace social media as a dynamic tool to advance research and cultivate a globally connected scientific community.

Efficacy of Antimicrobial Intravesical Treatment for Uncomplicated Recurrent Urinary Tract Infections: A Systematic Review

Manish Man Pradhan
Assistant Professor, Department of Urology and Kidney Transplant Surgery,
Tribhuvan University Teaching Hospital, Nepal

The rise in antimicrobial resistance has called for novel solutions for treatment of recurrent urinary tract infections. Recurrent urinary tract infections are defined by the occurrence of at least two episodes in six months or three within a year. Infections associated with virulent pathogens have become increasingly difficult to manage and often require higher doses or alternative medications. With a paucity of new antibiotics on the horizon, changing the route or regimen of current antibiotic use has become the subject of increased attention. A potential way forward has been the use of intravesical antibiotics, which have been shown to have greater effect on bacteria at a local level while reducing systemic absorption and its associated side effects.

Instillation of therapeutic agents into the bladder to combat recurrent urinary tract infections has been part of clinical practice since the 1960s and usually reserved as end of line strategy. Although this technique has been around for decades, there is lack of concrete evidence for its use due to lack of trials in this topic. Of the few systematic review available to draw the conclusion from, all have shown that the intravesical antibiotics have great promise in minimizing antimicrobial resistance in those patients who have previously grown multi-resistant uropathogens.

Intravesical antibiotics has been used both for treatment and prevention of the recurrent UTIs. The antimicrobial commonly used is gentamicin, neomycin/polymyxin, neomycin or colistin in most of the studies. Overall, a good reduction in symptomatic UTI has been seen in most cases, with good short-term success rate in the prophylaxis as well as treatment groups and very few discontinuation rates. There was also change in the sensitivity of organisms in almost one third of the cases in both treatment and prophylaxis groups.

The side effects were minor and included allergy, suprapubic discomfort, autonomic dysreflexia, urinary tract infections and diarrhoea.

In summary, intravesical antimicrobial instillation seems to be a relatively safe and effective method for the prophylaxis and treatment of recurrent UTIs, especially in the short term. It is an alternative treatment modality in high-risk patients predisposed to UTIs where all other forms of systemic treatments have failed.

Preventing Catheter-Associated Urinary Tract Infections (CAUTI) and the Importance of Catheter Care

Marinelle Doctor
Nepean Hospital, Australia

Catheter-associated urinary tract infections (CAUTIs) are a prevalent issue within urology, significantly impacting patient health, healthcare costs, and length of hospital stays. This presentation emphasizes the dual approach of preventing CAUTIs through diligent catheter care and adherence to best practices in urological procedures.

Effective prevention strategies begin with a comprehensive understanding of catheter care protocols. This includes the selection of appropriate catheter types based on the clinical indication, ensuring sterile techniques during insertion, and implementing maintenance procedures that prioritize hygiene. Educating healthcare professionals and patients about the critical aspects of catheter upkeep, such as regular cleaning of the insertion site and monitoring for signs of infection, forms the cornerstone of CAUTI prevention.

Continuous evaluation and auditing of catheter usage practices in clinical settings allow for the identification of areas needing improvement. Evidence shows that employing a multidisciplinary approach—engaging nurses, physicians, and infection control specialists—enhances adherence to evidence-based protocols, reducing CAUTI rates significantly.

Furthermore, fostering an environment that encourages open communication between healthcare providers and patients can lead to greater awareness of catheter-related risks and prompt reporting of potential complications.

In conclusion, preventing CAUTIs hinges on rigorous catheter care practices combined with robust education and collaboration among healthcare teams. This session aims to prompt discussion on refining catheter care protocols and exploring innovative measures to minimize CAUTIs in urological practice.

Keywords: CAUTI, catheter care, infection prevention, urology, healthcare practices.

Dispelling Myths and Cultivating Hope in the Cancer Journey: A Palliative Care Perspective

Nuraishah Binte Zulkifle
Nurse Clinician and an Advanced Practice Nurse
Division of Palliative and Supportive Care (DSPC), National Cancer Centre Singapore (NCCS)

The cancer journey is often fraught with fear, uncertainty, and misconceptions that can deeply affect the emotional and physical well-being of patients and their families. In this 15-minute presentation, we will explore common myths surrounding cancer and its treatment, focusing on the misbeliefs that cancer is always a death sentence and that palliative care is only for end-of-life care. By dispelling these myths, we will shed light on the role of palliative care in improving quality of life, offering relief from symptoms, and providing holistic support throughout the course of the disease.

A key part of this discussion will involve rethinking the concept of hope, showing how it can evolve from hopes for cure to hopes for comfort, control, and meaningful experiences. We will also emphasize the importance of clear communication between healthcare providers, patients, and families to foster trust, dispel fear, and empower patients to take an active role in their care. Through sharing a story one patient, this talk aims to equip practitioners and caregivers with strategies to foster hope, reduce suffering, and enhance the cancer journey for patients and families.

Revolutionizing BPH Progression Prediction with Machine Learning Models

Bhojraj Luitel
Assistant Professor, Department of Urology and Kidney Transplant Surgery,
Tribhuvan University Teaching Hospital, Kathmandu, Nepal
Email: drbhojraj@gmail.com

Introduction and Objectives: BPH is a progressive disease with worsening of symptoms over time. There are multiple variables that can predict the natural course of BPH with and without treatment. Recent addition of AI/ML in the urological field has opened the door to predict progression of BPH symptoms. This Scoping review aims to review the current role of machine learning models to predict the progression of BPH and to prepare a conceptual framework for future studies.

Materials and Methods: A scoping review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses extension for scoping review (PRISMA-ScR) guidelines. Electronic database searches and manual searches of literature, including websites of key publishers were conducted. Using the Population, Intervention, Comparison and outcome (PICO) framework, this review included: patients with BPH or with male LUTS, factors affecting BPH progression, prediction of BPH progression using Machine learning models and conceptual framework.

Results: Out of the literature searched only Six articles met the inclusion criteria. There is paucity of literature related to this topic despite millions of patients treated for BPH. Historical data shows that Prostate size, high IPSS score, high PSA, Low Qmax, high PVR and increasing age are independent predictors of BPH Progression. Newer predictors of BPH progression are: Frailty Index, Sonographic parameters- IPP, DWT, Estimated bladder weight, Molecular markers-mRNA expression of α-receptor subtypes, α-receptor density in Prostate and prostatic adenoma, Expression of 5α-reductase type2 in prostatic tissue and Inflammatory markers (IL-8). Out of ML algorithms used for predictive analytics- beyond logistic regression and Fuzzy Logic, SVM, XG Boost, Decision Tree/Random Forest, KNN, Naïve Bayes and Neural Network may give better prediction. Multivariate conceptual framework for future study is also created by us.

Conclusion: Recent literature in prediction of BPH progression using machine learning is not that robust. Still there is a lack of well-designed training, validation and testing ML supported analytical study in this area.

Key Words: BPH progression, prediction, machine learning, AI

Immune Therapy in Advanced and Metastasis UTUC

Tan Ai Lian
Clinical Oncologist
Penang General Hospital

Patient with mUC has been treated for decades with platinum based chemotherapy, using different regimen in combination or sequencing of chemotherapeutic agent has not result in significant increase in survival to date, The development of new agents including immune check point inhibtors (ICIs), antibody drug conjugates (ADC) has revolutionized the management of advanced urothelial cancer. These novel drugs are not only improving OS but also significant increasing the chances of achieving deeper, more durable response for a subset of patient. However, we do not have biomarkers that can easily be incorporated into daily practice to predict which patients will respond to the treatments we have, it is urgent to try to identify who will not benefit from the novel therapies to avoid toxicities and financial consequences.

Opening the doors to meaningful Milestones in the treatment of Prostate Cancer[1-5]

Lanzotred

Enzalutamide Soft Capsules 40mg

References:

1. Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine. 2012;367(13):1187-97.
2. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. New England Journal of Medicine. 2014;371(5):424-33.
3. Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. New England Journal of Medicine. 2018;378(26):2465-74.
4. Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. New England Journal of Medicine. 2019;381(2):121-31.
5. Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. Arches: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. Journal of Clinical Oncology. 2019;37(32):2974-86.

Abbreviated Product Information

Trade Name: Lanzotred soft capsules. **Active Ingredient:** Each capsule contains: Enzalutamide 40 mg. **Therapeutic Indications:** Lanzotred is indicated for: • The treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). • The treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC). • The treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. • The treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy. **Dosage & administration:** The recommended dose is 160 mg enzalutamide (four 40 mg capsules) as a single oral daily dose. Medical castration with an LHRH analogue should be continued during treatment of patients not surgically castrated. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. Women who are or may become pregnant. **Warnings & precautions:** *Risk of seizure:* Use of enzalutamide has been associated with seizure. The decision to continue treatment in patients who develop seizure should be taken case by case. *Posterior Reversible Encephalopathy Syndrome:* There have been rare reports of posterior reversible encephalopathy syndrome (PRES) in patients receiving enzalutamide. *Concomitant use with other medicinal products:* Co-administration with warfarin and coumarin-like anticoagulants should be avoided. If enzalutamide is co-administered with an anticoagulant metabolised by CYP2C9 (such as warfarin or acenocoumarol), additional International Normalised Ratio (INR) monitoring should be conducted. *Renal impairment:* Caution is required in patients with severe renal impairment as enzalutamide has not been studied in this patient population. *Severe hepatic impairment:* An increased drug half-life has been observed in patients with severe hepatic impairment, possibly related to increased tissue distribution. The clinical relevance of this observation remains unknown. *Recent cardiovascular disease:* There are no data of its use in patients with recent myocardial infarction (in the past 6 months) or unstable angina (in the past 3 months), New York Heart Association Class (NYHA) III or IV heart failure except if Left Ventricular Ejection Fraction (LVEF) ≥ 45%, bradycardia or uncontrolled hypertension. This should be taken into account if enzalutamide is prescribed in these patients. *Use with chemotherapy:* The safety and efficacy of concomitant use of Lanzotred with cytotoxic chemotherapy has not been established. *Excipients:* Lanzotred contains sorbitol (E420). Patients with rare hereditary problems of fructose intolerance should not take this medicinal product. *Hypersensitivity reactions:* Hypersensitivity reactions manifested by symptoms including, but not limited to, rash, or face, tongue, lip, or pharyngeal oedema, have been observed with enzalutamide. *Contraception:* A condom and another form of birth control must be used during and for 3 months after treatment. Data have shown reproductive toxicity. **Undesirable effects:** The most common adverse reactions are asthenia/fatigue, hot flush, fractures, and hypertension. Other important adverse reactions include fall, cognitive disorder, and neutropenia. Seizure occurred in enzalutamide-treated patients. **Storage:** Store below 30°C. **Shelf Life:** 36 Months. **Presentation:** PVC/ACLAR-Aluminium blisters of 4 soft capsules. 28 blisters are placed in a carton along with the Pack Insert (112 Soft Capsules).

Full information available on request. Please consult full prescribing information before prescribing.

For Healthcare Professionals Only.

R1301723-MYS-CCI-141020-A4670

Dr. Reddy's Laboratories Malaysia Sdn. Bhd. (1238154-X)
Unit No. SO-29-07 and SO-29-08, Menara 1, Strata Office, No. 3, Jalan Bangsar, KL Eco City, 59200 Kuala Lumpur, Malaysia. Tel: +603 8679 1002 | Email: info.mys@drreddys.com

IQNYDE
Sildenafil Citrate

Transforming Lives with Confidence and Intimacy



- Bioequivalent to the originator
- Well-tolerated
- Fast time to onset: 30 minutes
- Long Duration of effect: 4 hours

Scan QR
Abbreviated Prescribing Information (API)

For Healthcare Professionals Only
pharmaniaga®

PHARMANIAGA MARKETING SDN BHD (198401005734)
No. 7 Lorong Keluli 1B, Kawasan Perindustrian Bukit Raja Selatan, Seksyen 7,
40000 Shah Alam, Selangor Darul Ehsan, Malaysia.
Tel: 603-3342 9999 Fax: 603-3344 2222 Customer Care Line: 1-800-888-313
Email: customercare@pharmaniaga.com Website: www.pharmaniaga.com

Exhibitors Floor Plan



Company	Booth
Surgimedic Tech Sdn Bhd	1,4,3
IHH Healthcare Malaysia	2
Ipsen Pharma Singapore Ptd Ltd	5 & 8
Viatris Sdn Bhd	6 & 7
Johnson & Johnson Sdn Bhd	9 & 10
Astellas Pharma (M) Sdn Bhd	11 & 12
GSK	13 - 16
Boston Scientific (M) Sdn Bhd	17 & 20
AstraZeneca Sdn Bhd	18 & 19
UMMI Surgical Sdn Bhd	21 & 24
Medi-Life Sdn Bhd	22
Zuellig Pharma (M) Sdn Bhd	23
Edaptechnomed (M) Sdn Bhd	25
Transmedic Healthcare Sdn Bhd	26
MKs Medic Sdn Bhd	27
Dr. Reddy Laboratories (M) Sdn Bhd	28
Merck Sharp & Dohme (Malaysia) Sdn Bhd	29
Medtronics	30
Mega Lifesciences Sdn Bhd	31
SYS Healthcare Sdn Bhd	32

Company	Booth
SEPLOU	33
H & A Medical Supply Sdn Bhd	33A
DTG Medical Sdn Bhd	34 & 39
Orient Europharma (M) Sdn Bhd	35
Abbott Laboratories (M) Sdn Bhd	36 & 37
Pacific Edge New Zealand	38
EP Plus Group Sdn Bhd	40
Rapha Medical Sdn Bhd	40A
DKSH Malaysia Sdn Bhd	41
Biobot Surgical Pte Ltd	42
Novugen Pharma Sdn Bhd	43 & 46
IBS Medical Equipments Sdn Bhd	44 & 45
Pro Element Technology Sdn Bhd	47
Intega Sdn Bhd	48
Evomedic Sdn Bhd	41A & 48A
Aspen Medical Products Malaysia SDN BHD	49
My Medic Resources	52
Ferring Sdn Bhd	53
QST Technologies (M) Sdn Bhd	54
Olympus (M) Sdn Bhd	55 & 56

Exhibitors Profile

Platinum SPONSORSHIP

Booth **17 & 20**

Boston Scientific (Malaysia) Sdn Bhd

D-36-01, Menara SUEZCAP 1, KL Gateway, No. 2 Jalan Kerinchi, Gerbang Kerinchi Lestari, 59200 Kuala Lumpur.
Tel : 03-7808 8000 | Website : www.bostonscientific.com/en-MY/home.html

Boston Scientific is dedicated to transforming lives with less-invasive technologies engineered to diagnose and treat a wide range of medical conditions. We're dedicated to collaborating with healthcare professionals to develop a broad portfolio of meaningful innovations that improve outcomes, reduce costs, increase efficiencies and—most importantly—help more people in more places around the world live longer, healthier lives. Our work in health care is about addressing patients' critical needs, expanding access to care and helping improve outcomes so people can lead longer, better lives, by helping physicians diagnose and treat complex cardiovascular, vascular, digestive, oncological, neurological, urological and pelvic health diseases and conditions.

Booth **13 - 16**

GlaxoSmithKline Pharmaceutical Sdn Bhd

HZ.01, Horizon Penthouse, 1 Powerhouse 1, Persiaran Bandar Utama,
Bandar Utama 47800 Petaling Jaya, Selangor
Tel: +603-2037 9808 | Fax: +603-7731 6887
Malaysia | GSK

GSK is a global biopharma company with the ambition and purpose to unite science, technology, and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by end of 2030. Our bold ambitions for patients are reflected in new commitments to growth and a step- change in performance. We prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune-system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.

Exhibitors Profile

Gold SPONSORSHIP

Booth **11 & 12**

Astellas Pharma Malaysia Sdn Bhd

Suite 18.05, Level 18, CentrePoint North Tower, Mid Valley City, Lingkaran Syed Putra, 59200 Kuala Lumpur
Tel : +603-2022 6999 | Fax : +603-2022 6988/977 | Website : www.astellas.com

Astellas Pharma is a global pharmaceutical company dedicated to improving the health and well-being of people worldwide. Headquartered in Japan, Astellas focuses on the discovery, development, and commercialization of innovative therapies in areas such as oncology, urology, immunology, and neurology. The company is driven by cutting-edge research and technology, striving to address unmet medical needs and provide patients with life-changing treatments. With a commitment to sustainability and ethical business practices, Astellas is a leader in advancing healthcare solutions across the globe.

Booth **18 & 19**

AstraZeneca Sdn Bhd (69730-X)

The Bousteador Tower, Level 12, No. 10, Jalan PJU 7/6, Mutiara Damansara,
47800, Petaling Jaya, Selangor, Malaysia.
Tel : +603-7624 3888 | Fax : +603-7624 3999

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development, and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

In Malaysia, we are currently one of the top pharmaceutical companies and we are committed to continued innovation, close customer relationships, people development and an ethical responsible approach to business, with an aim to make a difference to the lives of patients and the healthcare professionals.

Our Malaysia marketing company- AstraZeneca Malaysia Sdn Bhd, was established in 1981 and in 2019, the company announced a commitment to invest more than RM500 million (USD125m) in Malaysia over the next five years demonstrating a strengthening commitment towards patients, innovation and talent development in the country and rolling out new robotic and cognitive technology designed to improve efficiency and drive productivity across the Company's global operations.

In addition, a new Global Business Services hub will be equipped with cutting-edge robotic technology and automation to support financial, accounting and business services for AstraZeneca operations in the Asia Pacific region. The Robotic and Cognitive Centre will deliver 'digital disruption' in day-to-day operations, bringing greater efficiency and improving productivity that will be scaled across global operations using Robotic Process Automation, mimicking human actions by performing repetitive rules-based tasks across multiple applications.

AstraZeneca Malaysia marketing company's vision is to push the boundaries of science to deliver life-changing medicines that addresses unmet medical needs in non-communicable diseases such as Cardiovascular, Diabetes, Renal Diseases and Cancer as well as Respiratory Illnesses.

We are aiming to treat, prevent, modify and in the future, even cure. It is only by enhancing our understanding of disease biology and uncovering new ways of targeting the drivers of disease that we will create the next generation of therapeutics across our main therapy areas.

Booth 34 & 39

Device Technologies

3A-03, Wisma Mont Kiara, 1, Jalan Kiara, 50480 Kuala Lumpur, Malaysia.
Toll-Free Number :1800 812 011 | Tel: +603-2779 2586 | Email: customers.my@devicetechnologies.asia

Introducing Device Technologies

Device Technologies is the largest and leading medical technology distributor in Australia and New Zealand and has also expanded into Asia. We have been in the business for over 30 years now and we remain committed to continuously improving and positively impacting the healthcare communities we serve.

More about Device Technologies

Device Technologies has been successfully providing hospitals and healthcare professionals with superior medical solutions since 1992. With over 200 trusted brands and over 1000 highly skilled staff in Australia, Hong Kong, Malaysia, New Zealand, Philippines, Singapore, Thailand, and Vietnam - Device Technologies is dedicated to improving patients' lives through leading-edge technology services.

What can you expect from Device Technologies?

Here at Device Technologies, we strive for innovation, collaboration, taking ownership, and conducting good business in everything that we do. From the consulting room to the operating theatre, the Device Technologies vision is to enable superior health outcomes. By connecting healthcare professionals with the finest medical technologies and supplies in the market, Device Technologies is helping them to deliver the best care possible. Behind every brand distributed by Device Technologies is the concept that we deliver leading technology into the most capable hands. We nurture the relationship between distributor and healthcare professionals, guiding the process from concept to delivery, and beyond. After quickly expanding our footprint in Asia with the opening of 6 offices in Hong Kong, Malaysia, Philippines, Singapore, Thailand, and Vietnam since December 2019, we are focused on further broadening our expertise into the region and improving more lives, one medical technology or solution, at a time.

Booth **5 & 8**

Ipsen Pharma Singapore Ptd Ltd

Twenty Anson, 20 Anson Road #10-03, 079912 Singapore

Ipsen is a French leading global mid-size biopharmaceutical company headquartered in Paris, France focusing its efforts where unmet medical needs are greatest. Ipsen develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Rare Disease and Neuroscience. We have over 5000 employees worldwide and our medicines are registered in more than 100 countries, with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centres around the world.

Booth **1, 3 & 4**

Surgimedic Tech Sdn Bhd

No 78B, Jalan Teknologi 3/9, Bistari De Kota, Kota Damansara, 47810 Petaling Jaya, Selangor.
Tel: +603-6150 4046

As a primary focus, we operate as a distributor of urological instruments, offering technical support and services for surgical appliances. This includes leasing and renting lasers to both government and private hospitals across Malaysia.

Our utmost priority lies in delivering exceptional services to our patients, accomplished through our team of professionally trained technicians proficient in handling surgical appliances and urological services. We hold our customers in high regard, striving to deliver outstanding products and services consistently.

Our Vision
Being a trailblazing leader in urology instruments, we aim to empower professionally with inventive and state-of-the-art solutions that enhance the lives of patients.

Our Mission
Innovation and Research: We commit ourselves to continuous research and development, harnessing the latest technologies and ideas to create advanced urological instruments that enhance medical outcomes and patient experiences.

Quality and Precision: We uphold the highest standards of quality, ensuring that our urology instruments are precise, reliable, and safe for medical professionals and patients alike.

Customer-Centric Approach: Our focus remains on understanding and fulfilling the unique needs of our customers, building strong relationships based on trust and exceptional service.

Global Reach: We aim to expand our reach globally, collaborating with healthcare providers and institutions around the world to make our urology instruments accessible to all in need.

Booth **21 & 24**

UMMI Surgical Sdn Bhd

No.10 (1st Floor), Jalan Pendaftar U1/54, Temasya Industrial Park, 40150 Shah Alam, Selangor, Malaysia
Tel: +603-5569 6799 | Fax: +603-5569 8799 | Email: info@ummisurgical.com.my

About Us

UMMI Surgical Sdn Bhd is the exclusive distributor for Karl Storz Endoscopy in Malaysia. We commenced business activities in 2009, upon our appointment by Karl Storz. Karl Storz (www.karlstorz.com) produces the highest quality rigid and flexible endoscopes, instruments and equipment across 18 different medical specialties and is the world's most recognized brand for minimally invasive surgery products.

Our Values

We are responsible to our customers. We take responsibility to ensure the products are supplied in the same condition they left the factory and the end users are able to use them to achieve the desired results they're intended for, surgically or medically; to benefit the patients. We commit ourselves to provide the support needed for the optimum utilization of the products. We are responsible to our people. They are our greatest assets. Taking pride in what we do, each and every member of our team contributes to deliver values to our customers. UMMI Surgical provides solutions, achieves results and earns reputation via its people. We take great effort to provide comfortable working environment and ensure the well-being of our people. We continuously invest in leadership and management programmes to nurture, develop and empower our people. We believe when people feel they belong and are secured; they consistently produce quality works and act in the best interest of the company. We are responsible to our principal. As a partner, we are committed to market the products in the most responsible manner and we believe we deliver the best value to the customers by working closely with our principal.

Our Motto - Making A Difference

At UMMI Surgical, we strive to provide the best solutions for our customers. This can be achieved by delivering excellent products with the commitment and professionalism of our people in marketing; pre-sales and after sales services; as well as technical support. By giving our best in everything we do, we believe we can make a difference in helping our customers provide the best patient care. UMMI Surgical and Karl Storz are committed to; and heavily support the training and educational activities of surgical and medical personnel in the area of endoscopy. Within our own capacity, we help to enhance and facilitate the learning activities. By working in partnership with our customers, we hope to make a meaningful contribution towards achieving better patient outcome.

Our Milestones

2009 – Commenced business from a rented shop lot at Ara Damansara
2013 – By November, moved into our very own premise of approximately 22,000 square feet at Temasya Industrial Park, occupying half of the space we share with Medi-Life Sdn Bhd

Booth **22**

Medi-Life (M) Sdn Bhd

No. 10, Jalan Pendaftar U1/54, Kawasan Perindustrian Temasya, 40150 Shah Alam, Selangor.
Tel: +603-5569 2699 | Fax: +603-5569 3299 | Email Address: info@medi-life.com.my

We are distributor of medical equipment and devices in Malaysia, providing high quality, state of the art medical advances to leading hospitals in Malaysia.

Our corporate slogan, "When Quality Healthcare Matters" simply means that we've committed ourselves to making a positive difference in the lives of patients and those who care for them, by helping our customers deliver safer, efficient and effective care.

Medi-Life started with a team of four personnel and one agency line in year 2008 and with further acquiring of agency lines, today we have staff strength of over 60 people and total of 23 agency lines. With such a wide and comprehensive range of products we hope to provide our customers a one-stop center of total solution.

Booth **35 & 37**

Abbott Laboratories (M) Sdn Bhd

27-02, Level 27, Imazium, No. 8, Jalan SS 21/37, Damansara Uptown, 47400 Petaling Jaya, Selangor
Office: +603-7988 7132

ABBOTT IN MALAYSIA

For more than a quarter of a century, Abbott has been dedicated to helping people in Malaysia live healthier lives through a diverse range of science-based nutritional products, diagnostic tools, pharmaceuticals, and vascular devices. Headquartered in Imazium, Selangor, Abbott was incorporated in Malaysia as a private limited company in 1987 and then as a legal entity in 2014 as Abbott Manufacturing.

ADVANCING HEALTH AND WELLNESS IN MALAYSIA

Abbott in Malaysia reflects our company's dedication in offering high-quality products and finding lasting solutions to unique local health challenges.

Whether we're developing diagnostic tests so local patients can benefit from the latest treatments or revolutionizing the way people monitor their glucose, we're at the forefront of science and innovation in everything we do.

PROVIDING WORLD-CLASS PRODUCTS

Abbott offers an array of leading products in Malaysia to help people live healthier, fuller lives.

Nutrition

We understand that proper nutrition is the foundation for living the best life possible. That's why we develop science-based nutrition products for people of all ages. Our products help little ones and children grow, keep bodies strong and active, and support the unique nutrition needs of people with chronic illnesses — to make every stage of life a healthy one. Under the category of pediatric nutrition products, Abbott Malaysia carries growing-up milk brands, such as Similac® Gain Plus, Similac® Gain Kid, PediaSure® Complete, Isomil® Plus and Similac® Total Comfort Plus.

Diagnostics

Diagnostic testing is a compass, providing information that helps in the prevention, diagnosis, and treatment of a range of health conditions. Abbott's life-changing tests and diagnostic tools put the power of health in the hands of people in all parts of the world. Our innovations in diagnostics aid physicians in Malaysia with informatics solutions, molecular and laboratory diagnostic testing.

Established Pharmaceuticals

In Malaysia, Abbott seeks to become a trusted partner by providing high-quality, affordable branded generic pharmaceuticals to a wider range of people across the country, and we continuously improve our medicines to make them better, easier to administer and faster to act.

Vascular

Our breakthrough vascular technologies help people with cardiovascular disease regain their health, so they can live fuller, more active lives. Abbott focuses on improving treatment options for people with coronary artery disease, mitral regurgitation and peripheral artery disease. We're working on timely advances and innovative technologies that have the potential to improve the way doctors treat people with vascular diseases.

Diabetes

We believe people with diabetes should have the freedom to enjoy vigoro us, active lives. That's why we're focused on helping them manage their health more effectively with products that provide accurate data to drive better informed decisions. We're revolutionizing the way people monitor their glucose with, easy-to-use diabetes products. In Malaysia, our line of FreeStyle® glucose monitors and test strips helps people with diabetes better manage their glucose levels.

SUPPORTING OUR COMMUNITY

We're dedicated to making a positive impact in the communities where we live and work, through partnerships that promote better quality of life for people across Malaysia.

Booth 9 & 10

Johnson & Johnson Sdn Bhd

Level 8, The Pinnacle, Persiaran Lagoon, Bandar Sunway, 46150 Petaling Jaya, Selangor Darul Ehsan, Malaysia
Tel: +603-7661 4500 | Fax: +603-7610 0519 | Website : http://www.jnj.com

Johnson & Johnson Sdn Bhd is committed to redefining healthcare : connecting the best if Health&Care for every provider, for very patient, for everyone,

Johnson & Johnson Innovative Medicine is leading where medicine is going. Patients inform and inspire our science-based innovations, which continue to change and save lives. With rigorous science and compassion, we confidently address the most complex diseases of our time and unlock the potential medicines of tomorrow. Therapeutic areas include Oncology, Immunology, Neuroscience, Cardiovascular, Pulmonary Hypertension, and Retina. Specifically for Oncology, one of our commitments is to improve patients diagnosed with genitourinary cancers.

Johnson & Johnson MedTech segment strives to provide that the next generation of smarter, less invasive, and more personalized medical technology treatments to tackle the most pervasive and complex health challenges for people around the world. Focus areas include Orthopedics, Surgery, Cardiovascular and Vision.

Booth **55 & 56**

Olympus (Malaysia) SDN BHD

Unit T2-L05-1, PJ33, No. 3, Jalan Professor Khoo Kay Kim, Seksyen 13, 46200 Petaling Jaya, Selangor, Malaysia
Tel: +603-7650 8990

At Olympus we believe everyone should have the opportunity to live life to the full. Every day we are advancing medical technology solutions to help people everywhere fulfill their desires, their curiosity, their dreams, their ambitions, and their lives.

It's a philosophy we call: True to Life

True to Life sits at the heart of Our Purpose of "Making people's lives healthier, safer and more fulfilling." For over 100 years Olympus has been pioneering innovative technologies and solutions that made the previously invisible visible and we have a long legacy of delivering minimally invasive "see and treat" therapies that help detect, prevent and treat diseases.

Olympus collaborates with incredible professionals across the globe who are dedicated to ensuring people have the health to live fulfilling lives. Our medical technologies help them elevate the standard of care and create moments of fulfillment for all.

This is why Olympus is True to Life. More than a technology - a philosophy.

Booth **6 & 7**

Viatris Sdn Bhd

15-03 & 15-04, Level 15, Imazium, No. 8, Jalan SS 21/37, Damansara Uptown,
47400 Petaling Jaya, Selangor, Malaysia
Tel: +603-7733 8005

Viatris is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India.

Booth **S23**

Zuellig Pharma (M) Sdn Bhd

No. 15 Persiaran Pasak Bumi, Section U8, Perindustrian Bukit Jelutong 40150 Shah Alam, Selangor, Malaysia
www.zuelligpharma.com

ZP THERAPEUTICS
making healthcare more accessible

ZP THERAPEUTICS
The go-to commercialisation partner for the healthcare industry, and a valued partner in providing innovations to the healthcare community and expanding patient access.

ZP Therapeutics is the partner of choice for companies looking for a sales and marketing partner in Asia. With offices in 13 markets across Asia and over 2,500 associates, our commercial excellence, in-market capabilities and strong ethical principles have driven the group's success as a trusted partner for the healthcare industry.

We are a catalyst in improving patient journeys and healthcare outcomes and are committed to making healthcare accessible, fuelled by agility, resilience, integrity and our passion to deliver excellence in everything we do.

Exhibitors Profile (Others)

Booth **49**

Aspen Medical Products Malaysia Sdn. Bhd 201201020269 (104761-W)

Unit 1302A, Level 13A, Uptown 1, 1 Jalan SS21/58, Damansara Uptown,
47400 Petaling Jaya, Selangor, Malaysia
Tel: +603-7733 9795 | Direct Tel: +603-7733 0368 | Mobile: +6016-442 5942
www.aspenpharma.com

Aspen Malaysia is a subsidiary of Aspen Pharmacare Holdings, a South African-based multinational pharmaceutical company with a 170-year heritage. Aspen focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets in more than 115 countries. In Malaysia, Aspen offers branded pharmaceutical products in various therapeutic categories, which includes urology, anaesthetics, thrombosis, critical care medications, high potency and cytotoxic drugs. Aspen is committed to act with integrity and aspired to improve the health and quality of life of patients.

Booth **42**

Biobot Surgical Pte Ltd

79 Ayer Rajah Crescent #04-05, Singapore 139955
Tel: +65-6351 1863 | Website: www.biobotsurgical.com

At Biobot Surgical, we are dedicated to redefining the standard of care in urology through technological innovation. Our flagship product, the iSR'obot Mona Lisa system, arms urologists with cutting-edge robotic precision and enhanced visualization for percutaneous transperineal procedures. And together with urologists we've completed over 23,000 procedures across the globe, including the US, China, Australia, Europe, and the Asia Pacific. Our focus remains on expanding the applications and accessibility of our technology, ensuring that both surgeons and patients worldwide benefit from the precision and care they deserve.

Booth **31**

BiO-LiFE Marketing Sdn Bhd (167808-V)

B-28-02, The Ascent, Paradigm, No.1, Jalan SS 7/ 26A, Kelana Jaya, 47301 Petaling Jaya, Selangor.
Tel: +603-7499 7999 | Fax: +603-7882 6388

BiO-LiFE Marketing is a healthcare company engaged in wellness with 32 years of existence in Malaysia. It has an able team of Nutritionists, Biochemists, Food technologists and Microbiologists that help bring relevant products to consumers.

BiO-LiFE Marketing became a part of Mega Lifesciences since its acquisition in Nov 2016. Mega Lifesciences is a leading pharmaceutical and nutraceutical company headquartered in Bangkok and publicly listed since 2014. Mega is actively involved in helping millions of people have access to safe, effective, world class quality nutritional & herbal supplements, OTC and ethical products.

Established in 1982, Mega Lifesciences is engaged in manufacturing, marketing, selling and distributing Medicines through its own offices and also through and extensive distributor network. Its world class manufacturing standards is backed by approvals from Thailand FDA, Australia TGA & German GMP.

Exhibitors Profile

Booth **41**

DKSH Malaysia Sdn Bhd

B-11-01, The Ascent, Paradigm, No. 1, Jalan SS7/26A, Kelana Jaya, 47301 Petaling Jaya, Selangor, Malaysia
www.dksh.com

DKSH is one of the oldest and largest Market Expansion Services providers in Malaysia. Headquartered in Petaling Jaya, Selangor, DKSH provides unparalleled market coverage, serving over 170 clients and thousands of customers nationwide. DKSH's mission is to help other companies and brands grow their business in new or existing markets. We do this by offering our business partners tailor-made solutions along the entire value chain to support them in successfully achieving their business objectives. In Malaysia, our business is divided into four specialized Business Units which include Consumer Goods, Healthcare, Performance Materials, and Technology.

Booth **28**

Dr. Reddy's Laboratories Malaysia Sdn Bhd

Unit No. SO-29-07 and SO-29-08, Menara 1, Strata Office,
No. 3, Jalan Bangsar, KL Eco City, 59200 Kuala Lumpur, Malaysia.

We started in 1984 with a modest investment and a bold vision. We were the first Asian pharma company outside Japan to list on the New York Stock Exchange in 2001. We are committed to the highest standards of compliance, ethics and quality in every activity that we undertake.

Our products and services are spread across our core businesses of Active Pharmaceutical Ingredients (API), generics, branded generics, biosimilars and over-the-counter pharmaceutical products around the world. We work towards meeting unmet patients' needs in the areas of gastro-enterology, cardiovascular, diabetology, oncology, pain management and dermatology. We are investing in businesses of the future including drug discovery, clinically differentiated assets and digital healthcare.

For four decades, Dr. Reddy's Laboratories has stood for advancing healthcare through access, affordability and innovation. Our work has been guided by our core tenets of deep science, progressive people practices and robust governance. 'Good Health Can't Wait' has become a movement and call to action for all of us, and good health encompasses people, planet and patients.

Today, with research and development centres, manufacturing facilities and commercial presence across the globe, we serve over half a billion patients worldwide. We are grateful for the trust our patients and stakeholders have had in us throughout our journey. We will continue to work on strengthening our core further and building the future of healthcare as we aim to touch the lives of over 1.5 billion patients by 2030.

Booth **25**

Edaptechnomed (M) Sdn Bhd

No. 16 (1st Floor) USJ 10/1B, Taipan Triangle, Subang Jaya 47620 Selangor, Malaysia.
Tel: +603-5634 9335 | Fax: +603-5634 9733

Edaptechonomed (M) Sdn Bhd is a specialized urology equipment company focusing on stone and prostate management.

Stone Management:
- Surgical Lasers: Holmium and TFL lasers from Quanta System, including Litho 30W, Litho 35W, Litho EVO , Cyber Ho (60W, 100W, 150W), Fiber Dust (TFL) and Fiber Dust Pro (TFL Pro).
- Irrigation Systems: Ureteroscopy irrigation solutions like Peditrol or Smart Bulb from Wismed.

BPH (Benign Prostatic Hyperplasia) Management:
- Surgical Lasers: Holmium and Thulium lasers from Quanta System, such as Fiber Dust, Fiber Dust Pro, Cyber TM Family, and Cyber Ho (60W, 100W, 150W).

Prostate Cancer Management:
- Detection: Micro-ultrasound fusion device (Exact Vu) from Exact Imaging.
- Therapy: Focal therapy solutions, including Focal One from EdapTMS.

Booth **40**

EP Plus Group Sdn Bhd 199701014075 (429571D)

Block C-3-1, Plaza Mont Kiara, No 2, Jalan Kiara, Mont Kiara, 50480 Kuala Lumpur, Malaysia.
Tel: +603-6205 2728 | Fax: +603-6205 2729 | Website: www.epplusgroup.com

About EP Plus Group

EP Plus Group is a regional healthcare corporation based in Kuala Lumpur, Malaysia, with a robust foothold in Singapore, Indonesia, and the Philippines. Since our inception in 1997, we have been driven by our mission to make innovative European medical possibilities – pharmaceuticals, medical devices and equipment – accessible to patients throughout Southeast Asia (SEA).

With more than 25 years of experience, EP Plus Group has built more than 10 niche European brands from zero to market leaders in Southeast Asia, through our 3 business units –

Pharmaceuticals, Fertility Sciences and Medical Aesthetics.
Today, we are the exclusive distributor of more than 15 principals of pharmaceutical and medical device products with over 30 brands, serving more than 10,000 healthcare professionals.

Our Vision
The leading healthcare group in Southeast Asia.

Our Mission
Enhancing lives through pharmaceutical and medical products.

Our Commitment
We are committed to:
- Achieving better disease management and treatment outcomes, together with our healthcare professionals;
- Adding value to all individuals that we meet - patients, employees, customers, business partners and community;
- Making a difference in improving lives.

EP Plus Group is always Innovating for Better Lives, especially within the community we serve, including patients, employees, customers, and business partners.

Exhibitors Profile

Booth **41A & 48A**

Evomedic Sdn Bhd (PJ Branch)

C-G-03 & C-1-03, Block C, Oasis Corporate Park,
No.2, Jalan PJU 1A/2, Ara Damansara, 47301 Petaling Jaya, Selangor.

Evomedic Sdn Bhd was established in 2017 as a distributor for medical devices, providing the sales and rental of products used mainly for Minimally Invasive Surgeries. Our aim is to provide access to the best solutions with innovative products, and to ensure that we deliver the best price-performance ratio at all times.

Booth **53**

Ferring Sdn Bhd

21-6, Block B, Jaya One, No. 72-A, Jalan Profesor Diraja Ungku Aziz
46200 Petaling Jaya, Selangor Darul Ehsan, Malaysia
Tel: +603-7960 3032 | Website: www.ferring.com

Ferring Pharmaceuticals is a privately-owned, research-driven, speciality biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine and maternal health, and in areas of gastroenterology and urology. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Our company was founded in 1950 and is headquartered in Saint-Prex, Switzerland. Ferring employs more than 7,000 people worldwide and markets its medicines in over 100 countries. Ferring Sdn Bhd is based in Petaling Jaya, Selangor, Malaysia and employs around 20 people. For more information, please contact 603-7960 3032.

Booth **33A**

H&A Medical Supply Sdn Bhd (760352-T)

CT-05-11 Corporate Tower Subang Square, Jalan SS15/4G, 47500 Subang Jaya, Selangor, Malaysia
Tel: +603-5636 6732

H&A Medical Supply Sdn Bhd was incorporated on JAN 2007 and located at Subang Jaya, Selangor.

H&A started with some Cardiology and Radiology accessories, and focused on interventional devices. The company then extended the service into Shock Wave Lithotripsy, Imaging Equipment, and Nuclear Medicine accessories.

H&A is strongly committed to provide quality products and after sales service to the customers

Exhibitors Profile

Booth **44 & 45**

IBS Medical Equipments Sdn Bhd

Headquarters: No.7-G, 3rd Mile Square Business Center, No.151, Old Klang Road
58100 Wilayah Persekutuan Kuala Lumpur
Tel: +603- 7971 4221

IBS Medic is dedicated to providing comprehensive solutions for the Urology sector in Malaysia. Our passionate team is committed to delivering the highest quality products and services, with customer satisfaction being our top priority. IBS Medic proudly offers cutting-edge technologies, including Intelligent Fusion Ultrasound, Holmium Lasers, Scopes, Irrigation Pumps, Suction and accessories. We strongly believe in innovation and continuously seek the latest advancements to meet our customers' needs. We look forward to providing you with world-class service and solutions.

Booth **2**

IHH Healthcare Malaysia

Level 6 Block A, Pantai Hospital Kuala Lumpur, 8 Jalan Bukit Pantai, 59100 Kuala Lumpur.
Tel: +603-2298 9898 | Website: www.ihhhealthcare.com/my

IHH Healthcare Malaysia is one of the largest private healthcare providers in Malaysia, with approximately 3,000 beds. Our healthcare network comprises 11 Pantai Hospitals, four Gleneagles Hospitals, Prince Court Medical Centre and Timberland Medical Centre, and is complemented by ancillary services including Premier Integrated Labs, Pantai Integrated Rehab and a chain of primary care clinics under Twin Towers Medical Centre. Our team of over 14,000 staff and more than 1,500 consultants are strongly committed to our aspiration to Care. For Good. where we prioritise patients' needs to deliver quality clinical outcomes.

IHH Healthcare Malaysia is part of IHH Healthcare, a world-leading integrated healthcare provider with presence in 10 countries, including its key markets of Malaysia, Singapore, Turkiye, India, and Greater China (including Hong Kong). IHH's portfolio of trusted brands include Acibadem, Mount Elizabeth, Prince Court, Gleneagles, Fortis, Pantai and Parkway. Our vision is to be the world's most trusted healthcare services network.

More information can be found at www.ihhhealthcare.com/my

Booth **48**

Intega Sdn Bhd

2nd Floor, No12B(B), Jalan SJ6, Taman Selayang Jaya, 68100 Batu Caves, Selangor Darul Ehsan, Malaysia.
Email: info@integahealth.com | Website: www.integahealth.com

Intega is a pharmaceutical and healthcare specialist with a proven track record in implementing business strategies for multi-national organizations in South East Asia. We offer market entry expertise for quality prescription drugs, particularly in the specialist fields of Oncology, the Central Nervous System, Cardiovascular, ICU and Urology, and for a wide range of medical devices and consumer health products. Our internationally trained team has many years of industry expertise across the South East Asia region that ensures we can efficiently and cost-effectively cover the market entry groundwork to ensure a speedy market introduction.

Exhibitors Profile

Booth **30**

Medtronic

B-23-01, The Ascent, Paradigm Mall, No. 1, Jalan SS7/26A, Kelana Jaya, 47301 Petaling Jaya, Selangor Darul Ehsan, Malaysia
Tel: +603-7883 8000 | Fax: +603-7886 4702

Medtronic
Engineering the extraordinary

About us Bold thinking. Bolder actions. We are Medtronic. We lead global healthcare technology and boldly attack the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world.

In everything we do, we are engineering the extraordinary.

Booth **29**

Merck Sharp & Dohme (Malaysia) Sdn Bhd

B-22-1 & B-22-2, The Ascent Paradigm, No 1, Jalan SS7/26A, Kelana Jaya, 47301 Petaling Jaya, Selangor, Malaysia
Tel: +603-7499 1600 | Website: www.msd.com

MSD

MSD Malaysia is a leading research-intensive biopharmaceutical company committed to saving and improving people's lives. MSD Malaysia is a subsidiary of Merck & Co., Inc., with headquarters in the Kenilworth, U.S.A, which is a global healthcare leader that discovers, develops, manufactures, and markets a broad range of innovative healthcare products.

Booth **52**

Mymedic Resources

No. 16-, 2, Jalan Utama Suria Tropika 1, Taman Suria Tropika, 43300 Seri Kembangan, Selangor.
Tel: +603-8958 5514

MMR MY MEDIC RESOURCES

MyMedic Resources was incorporated in March 2007, specialist in Laser application for Endourology work, with our new laser system and new technology for stone management, Thulium Fiber Laser (TFL) from E.M.S, we believed it will help urologist to perform surgery better and shorter the stone surgery time. Together with our Reusable and disposable RIRS scope from SEESHEEN, we hope we can give optimum surgery result for your patient.

Booth **43 & 46**

Novugen Pharma Sdn Bhd

3, Jalan Jururancang U1/21, Hicom-glenmarie Industrial Park,
40150 Shah Alam, Selangor

Novugen is a wholly owned subsidiary company of a UAE based group, SciTech International. With over 30 years of experience in the healthcare industry, the company is equipped with vast and successful experience of venturing into strategic healthcare businesses and development of world class healthcare facilities around the globe. Novugen's passion for science, bold global strategy and wealth of international experience prepared us to respond to complex challenges of bringing hard-to-source and technology-intensive pharmaceutical products to the market.

Novugen specializes in niche and difficult to formulate generics for all therapeutic areas of general and oncology medicines while meeting stringent global quality standards. With vertically integration from Active Pharmaceutical Ingredients (API) to Finished Products R&D and manufacturing based in Malaysia, it gives us greater control over the supply chain. Malaysia is also home to our state-of-the-art manufacturing facilities, designed by globally renowned European pharmaceutical engineering firm following stringent regulatory requirements by authorities across the globe including USFDA, EMA, PIC/S and WHO.

We are the first USFDA approved pharmaceutical company in Malaysia and the Only in Southeast Asia with manufacturing facilities focusing on oral solid dosage forms for general medicines and highly potent Oncology drugs. The accreditation by the U.S. federal agency positions us as the first pharmaceutical company in the country to manufacture high-quality medicines locally in Malaysia for the U.S. market. Our manufacturing facilities are also Halal compliant, a reflection of our commitment to respond to the increasing demand of Halal products in the local market and a testament to our purpose of serving the burgeoning demand of Halal products globally.

Novugen enhances in achieving the desired quality of our products with systematic Quality by Design (QbD) approach. With our robust team of professionals and scientists, advanced R&D centre and USFDA Approved manufacturing facilities in Malaysia, we are committed to ensure early access of high-quality products that lack robust generic alternatives due to their complexity. We strive to strengthen the accessibility of affordable and global quality standard products in Malaysia with same efficacy to medicines exported to the U.S.

Novugen's business outlook targets a wider market penetration globally. Our focus is on ASEAN, CIS, GCC, Africa & LATAM regions and expanding through distributor channels in the U.S., Europe and Canada markets. Today, Novugen is present globally with 5 offices worldwide, including, Malaysia, the U.S., Uzbekistan, UAE, and Pakistan. In 2030, we are targeting to enter the global market of 89 countries worldwide, covering all continents.

The people behind Novugen are united to achieve one common vision to be the largest and fastest growing pharmaceutical company in Southeast Asia by 2025, competing in global markets. Our aim is to make an impact on Malaysia's economy, being a self-sufficient nation, capable to supply quality medications locally and increasing the country's power to export. Devoted to the cause, we hold the highest standards of ourselves, finding ways to serve patients locally and all over the world with life-changing medicines.

Exhibitors Profile

Booth **35**

Orient Europharma (M) Sdn Bhd

No. E-08, Garden Shoppe, One City,Jalan USJ 25/1C, 47650 Subang Jaya,Selangor Darul Ehsan, Malaysia.
Tel: +603-8081 6637 | Fax: +603-8081 8137 | Email: oemsb@mail.ope.com.tw

Orient Europharma

OEP COMPANY INTRODUCTION:

Founded in 1982, Orient EuroPharma (OEP) became officially listed in the Taiwan Exchange in 2003. In the beginning, the Company was a prescription drug distributor, but has now become a full-scale, multinational pharmaceutical company. The core competencies of the Company not only include pharmaceutical innovation, R&D, manufacturing, sales and clinical trials, but has significantly increased the Company's operational efficiency through vertical integration to provide customers with more complete services.

From the very beginning of its establishment, OEP has focused on creating the subsidiary companies to develop and manufacture new drugs to meet real human needs. Moreover, the Company is committed to providing products and services that are valuable and unique. Currently, OEP has three major business focuses on prescription medicines, nutricare and anti-aging, respectively. Each business focus is not only committed to developing its individual brand, but also continues to seek cooperation opportunities with internationally renowned pharmaceutical companies.

Since 2000, OEP has successively established overseas subsidiaries in Singapore, Malaysia, Hong Kong and the Philippines. In 2006, the Company established subsidiaries in Mainland China, and is steadily cultivating the Asia-Pacific market and gradually reaching the goal of becoming a benchmark enterprise in the Asia Pacific.

The Company's core value - Through Integrity, United We Achieve and Be Remarkable, is manifested in every detail of the team effort to innovate and grow together.

Booth **38**

Pacific Edge Diagnostics Singapore Pte Ltd

PACIFIC EDGE LTD
CANCER DIAGNOSTICS COMPANY

Pacific Edge Limited is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA

Exhibitors Profile

Booth **47**

Pro Element Technology Sdn Bhd (906780-M)

18-34-A3, Persiaran Gurney, Gurney Tower, 10250 Georgetown, Penang, Malaysia.
Tel: +604-226 3286 | Fax: +604-227 3286 | Email: info@pro-element.com.my
Website: www.pro-element.com.my

Established in July 2010, Pro Element Technology Sdn Bhd is currently headquartered in Penang, the hub for Northern Malaysia, with sales and marketing network nationwide.

Pro Element Technology Sdn Bhd is certified with GDPMD and operating with the Establishment License for Medical Devices under the Medical Device Authority of Malaysia. As an importer, Pro Element Technology Sdn Bhd aimed to engaged in medical supplies, as well as any other beneficial bio and life sciences products. Our ultimate goal is to provide possible solutions or options for healthcare service providers as well as individual consumers. As a supplier, Pro Element Technology Sdn Bhd is established by aiming to provide excellent products via professional services with value-added elements in our service. Meeting customers' needs is our fundamental goal.

Pro Element Technology Sdn Bhd strives to be an excellent partner with our principals and reputable service providers for our clients. Bridging the two, principals and users, Pro Element Technology Sdn Bhd is committed to grow together with the industry.

Booth **54**

QST Technologies (M) Sdn Bhd

Unit No.10.05, 10th Floor Menara K1, No.1, Lorong 3/137C, Off Jalan Kelang Lama,
58000 Kuala Lumpur, Malaysia.
Tel: +603-7773 3197 / 3198 | Fax: +603-7773 3196 | Website: www.qsttech.com
Facebook: www.facebook.com/qsttech

QST was established in 2005 and focuses on providing products, services and solutions covering extensive Imaging portfolio such as Ultrasounds, MRIs, & X-rays. We take pride in providing innovative and effective solutions to the increasingly demanding Urology and Intraoperative imaging environment.

Exhibitors Profile

Booth **40A**

Rapha Medical Sdn Bhd

No. 2, Jalan Nilam 1/6, Subang Hi Tech Industrial Park, 40000 Shah Alam, Selangor.
Tel: +603-5621 0353 | Website: www.raphagroup.com

RAPHA MEDICAL

Rapha Medical is an integrated medical device solutions provider based in Malaysia.

We are able to supply medical devices and consumables to hospitals, clinics, laboratories, pharmacies and healthcare outlets throughout the country. We have partnerships with global corporations and have the experience of working with healthcare institutions in Malaysia.

Our mission is to provide high quality products and the best service support possible to our customers with the aim of advancing healthcare.

Cook Asia (Malaysia) Sdn Bhd

Unit 1602, Level 16, Uptown 1, No. 1, Jalan SS21/58, Damansara Utama, 47400 Petaling Jaya, Selangor Malaysia
Tel: +603-7669 3889 | Fax: +603 7669 3898 | Email: CS.Malaysia@CookMedical.com

A patient-first philosophy and innovative spirit have helped Cook become a leader in urology. With a focus on stone management and prostate health, we pride ourselves on providing quality solutions without compromise. By uniting with healthcare professionals around the world, we're committed to advancing treatment and making a difference, together.

以患者为先的理念和创新精神使库克成为了泌尿外科的领导者之一。我们专注于结石管理领域，提供不折不扣的高质量解决方案，并引以为傲。透过与全球的医疗专家合作，我们致力于联手促进治疗效果，并为泌尿外科专业带来改变。

(我们相信医生与产业合作是提供更好的医疗的关键。这是我们的核心信念。我们的教育和培训计划鼓励共享作业规范和学习使用库克的创新产品的新技巧。)

Booth **26**

Transmedic Healthcare Sdn Bhd (537463-D)

B4-1-1, Solaris Dutamas, No 1, Jalan Dutamas 1, 50480 Kuala Lumpur, Malaysia.
Tel: +603-6205 3888 | Fax: +(603) 6205 4062 | Email: enquiries@transmedicgroup.com

transmedic
advancing medical technologies

Established in 1980, Transmedic brings over 40 years of valuable industry experience, in-depth knowledge, and local expertise in cutting-edge medical technologies and treatments. Today, Transmedic is proud to be part of the EBOS Med Tech group, which also includes Australian Biotechnologies (allograft manufacturing), Cryomed (aesthetics division), and LifeHealthcare (ANZ distribution business). We are the leading independent medical technology distribution partner for world-class medical institutions and professionals in ASEAN+HK.

Booth **32**

SYS Healthcare Sdn Bhd (1217995-H)

No. 1-1 (1st Floor), Jalan Damai Raya 6, Alam Damai, 56000 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur.
Tel: +603-9108 4888 | Fax: +603-9102 4848

SYS HEALTHCARE

SYS Healthcare is a home-grown medical device distributor specialising in the fields of Urology, Gastroenterology, Otorhinolaryngology (ENT), General Surgery, O&G, Respiratory and CSSD. We strive for excellence and pride ourselves in continuously supporting Hospital services.

Congress Information

Conference Venue

SPICE Convention Centre,
SPICE, No. 108, Jalan Tun Dr. Awang,
11900 Penang, Malaysia.
Tel : 04-643 2525

Conference Secretariat

33rd Malaysian Urological Conference

Conference Secretariat
Malaysian Urological Association
Unit 6-5, Bangunan Perdagangan D6,
801 Jalan Sentul, 51000 Kuala Lumpur, Malaysia.
Website: www.muc2024.com
Email: malaysianurologicalassociation@gmail.com

Registration Fees Category

Category	Before 01.11.2024	After 01.11.2024
Pre-Congress Workshop 21 November 2024 Setia SPICE Convention Centre Limit : 150 pax	RM 250	RM 300
Full Delegate registration 22 & 23 November 2024 Setia SPICE Convention Centre	RM 1,000	RM 1,100
Nurse and Allied Health 22 & 23 November 2024 Setia SPICE Convention Centre	RM 650	RM 700
Nurse and Allied Health 23 November 2024 Setia SPICE Convention Centre (LImited to 50 pax only)	RM 150	RM 150

Registration Form

Please return the completed Form to the Secretariat with appropriate fees as early as possible to ensure receipt of the Conference bag and the complete set of conference materials upon checking in at the Conference Registration Desk. Photocopies of the form may be used.

Payment Details

Name of the Account: Malaysian Urological Association
Account Number: 514075606138
Bank Address : Malayan Banking Berhad, Lot AG 1-2 & AG 9-10, Block A, Plaza Pekeliling, No. 2, Jalan Tun Razak, 50500 Kuala Lumpur

Entitlement

Full registrants will be entitled to:
- Admission to all lectures, abstract sessions and symposiums
- Name Badge, Conference bags and Conference materials
- Admission to the exhibition areas
- Coffee/Tea
- Lunches

PRE-CONGRESS LIVE SURGERY
Date : Thursday, 21 November 2024
Time : 0900 – 1600 hrs
Venue : Ballroom 3, Lower Ground Floor, Setia SPICE Convention Centre, Penang

OPENING CEREMONY
Date : Friday, 22 November 2024
Time : 1010 – 1040 hrs
Venue : Ballroom 3, Lower Ground Floor, Setia SPICE Convention Centre, Penang

GALA DINNER
Entry : By ticket only
Date : Saturday, 23 November 2024
Time : 2000 – 2300 hrs
Venue : Ballroom 1, Lower Ground Floor, Setia SPICE Convention Centre, Penang

SCIENTIFIC SESSIONS
Date : Friday & Saturday, 22 & 23 November 2024
Time : 0800 – 1700 hrs
Venue : Ballroom 3, Lower Ground Floor, Setia SPICE Convention Centre, Penang

UROLOGY NURSING SYMPOSIUM
Date : 22 November 2024
Time : 1030 – 1700 hrs
Venue : Ballroom 4, Lower Ground Floor, Setia SPICE Convention Centre, Penang

Day 2 Breakout Session
Date : 23 November 2024
Time : 830 – 1500 hrs
Venue : Ballroom 4, Lower Ground Floor, Setia SPICE Convention Centre, Penang

MUA-NAUS Session
Date : 23 November 2024
Time : 830 – 1000 hrs
Venue : Function Room 7, Ground Mezzanine Floor, Setia SPICE Convention Centre, Penang

FAUA Trainees Session
Date : 23 November 2024
Time : 830 – 1000 hrs
Venue : Function Room 7 , Ground Mezzanine Floor, Setia SPICE Convention Centre, Penang

Congress Information

Poster Exhibition

1) As an alternative to the traditional printed paper poster, the Malaysian Urological Association is pleased to introduce e-posters to the 33rd Malaysian Urological Conference. E-posters will replace the printed posters and we are sure that you will share our enthusiasm for this innovative approach to poster presentation. As you will have uploaded your poster in advance there is no need to print and carry a poster to the meeting. This will save you the time and costs associated with printing and reduce the carbon footprint of the meeting. There will be monitors at the conference where all posters can be viewed.

2) Your e-poster should be produced using the Ms Powerpoint Poster template. The content of the presentation should be of a single slide. E-Posters of different dimensions may be skewed/stretched/truncated when displayed on the monitors at the conference unless they conform to the template. The poster should fill up the monitor display when its display is maximised, and not leave any white/black areas. All e-posters will be available for viewing on monitors placed at strategic location.

3) All abstracts accepted as moderated e-posters will be given a 3-minute podium presentation plus 1-minute discussion slot at the meeting on 25 November 2023. Presenters are required to check the e-Souvenir Programme or Secretariat for the allocated time and venue for the judging session. A template of the Ms Powerpoint slides to be used for the presentation. Moderated posters are eligible for the Best Poster Prize

4) Uploading of presentations will be available at the AV/Speaker Room at Function Room 3, Lower Ground Level, Setia SPICE Convention Centre, 0800hr, 21 November 2024 onwards. Presenters are encouraged to upload their presentations at 2000hr on the 21 November 2024.

5) All abstracts accepted as unmoderated e-posters can be viewed on monitors placed at strategic location.

Exhibition and Sponsorship

The industry exhibition, open to all registered delegates, forms an integral part of the Conference. Located at the Basement II Foyer, Shangri-La Hotel Kuala Lumpur, the exhibition provides an ideal opportunity for members of the pharmaceuticals industry, healthcare providers and publishers to discuss the latest products and services available in the field of Urology.

The Conference provides a platform for many high profile promotional opportunities through sponsorship. The Conference Organising Committee would like to express their sincere thanks to the organizations who have so far committed their support to the Event.

22 November 2024	0800hr – 1700 hr
23 November 2024	0800hr – 1700 hr

Insurance and Liability

The Organising Committee will not be liable for personal accidents, loss or damage to private properties of participants during the conference. Participants should make own arrangements with respect to personal insurance

Conference Website

Regularly updated information on registration, hotel reservation and scientific programme are available online at www.muc2024com.

Conference Language

The Official language of the Conference will be English.

Certificate of Attendance

A certificate of attendance will be issued to all delegates.

Letter of Invitation

Upon request, the Organising Committee will issue a letter of invitation. The sole purpose of the letter is to facilitate the delegate's travel and visa arrangements. The invitation does not imply provision of financial support. Letters of invitation may be requested by individuals from the Conference Secretariat by email : maluroassociation@gmail.com

Liability

The Organising Committee will not be liable for personal accidents, loss or damage to private properties of participants during the conference. Participants should make own arrangements with respect to personal insurance.

DISCLAIMER
Whilst every attempt will be made to ensure that all aspects of the Conference published in this announcement will take place as scheduled, the Organising Committee assumes no responsibility should any of these fail to materialize for any reason.

Acknowledgement

The Organising Committee of the 33rd Malaysian Urological Conference expresses its grateful thanks to the following for their contribution and support for the Conference.

Ministry of Health Malaysia
Malaysian Convention and Exhibition Bureau
Penang Convention and Exhibition Bureau

Platinum SPONSORSHIP

Boston Scientific (M) Sdn Bhd
GlaxoSmithKline Pharmaceutical Sdn Bhd

Gold SPONSORSHIP

Astellas Pharma (M) Sdn Bhd
AstraZeneca Sdn Bhd
Ipsen Pharma Singapore Pte Ltd
Surgimedic Tech Sdn Bhd
UMMI Surgical Sdn Bhd & STORZ
DTG Medical Sdn Bhd

Silver SPONSORSHIP

Abbott Laboratories (M) Sdn Bhd
Johnson & Johnson Sdn Bhd
Viatris Sdn Bhd
Zuellig Pharma Sdn Bhd

OTHER SPONSORS

Abbvie Sdn Bhd
Aspen Medical Products Malaysia Sdn Bhd
Biobot Surgical Pte Ltd
Bio-Life Marketing Sdn Bhd
Cook Medical
DKSH Sdn Bhd
Dr. Reddy's Laboratories (M) Sdn Bhd
Edaptechnomed (M) Sdn Bhd
EP Plus Group Sdn Bhd
Evomedic Sdn Bhd
Ferring Sdn Bhd
Getz Healthcare Malaysia Sdn Bhd
H & A Medical Supply Sdn Bhd
Healthcare Solution Sdn Bhd
IBS Medical Equipments Sdn Bhd
IHH Healthcare Malaysia
Intega Sdn Bhd
Medi-Life (M) Sdn Bhd
Medtronics
Merck Sharp & Dohme (Malaysia) Sdn Bhd
MKS Medic Sdn Bhd
My Medic Resources
Novugen Pharma Sdn Bhd
Olympus (M) Sdn Bhd
Orient Europharma (M) Sdn Bhd
Pacific Edge Diagnostics Singapore Pte Ltd
Pharmaniaga Berhad
Pro Element Technology Sdn Bhd
QST Technologies (M) Sdn Bhd
Rapha Medical Sdn Bhd
SEPLOU
Shenzhen HugeMed Medical Technical Development Co., Ltd
Sonacare Synergy (Asia) Sdn Bhd
SYS Healthcare Sdn Bhd
Transmedic Healthcare Sdn Bhd